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Siddhi Arun Chitre 
INVESTIGATING CHALCONES AND THEIR ABILITY TO INHIBIT THE HUMAN 
HSP60/10 CHAPERONIN SYSTEM AND COLORECTAL CANCER CELLS 
 
Colorectal cancer is the fourth commonly diagnosed cancer worldwide. Despite 
the different therapeutic strategies, the five-year survival rate of Stage IV colorectal 
cancer is 10%.  Hence, there is an urgent need to develop novel therapies.  
Heat shock proteins (HSPs) have attracted attention as anti-cancer targets since 
they are involved in cancer development. We are interested in targeting the HSP60/10 
chaperonin system, a.k.a GroEL/ES in bacteria. In healthy cells, HSP60/10 is in the 
mitochondrial matrix and assists in protein folding. However, recent studies demonstrate 
an aberrant localization of HSP60 in cytosol, which is hypothesized to promote tumor 
cell survival and proliferation. This mis-localization may make it possible to selectively 
target cancer cells.   
We recently reported results from two high-throughput screens (HTS) that 
identified several hundred inhibitors of the prototypical GroEL/ES chaperonin system 
from Escherichia coli, most of which also inhibited human HSP60/10. Several hits 
contained the “chalcone” core scaffold, which consists of two aromatic rings joined by an 
α,β-unsaturated ketone linker. We hypothesize that chalcone-based HSP60/10 inhibitors 
could be developed that will exhibit selective cytotoxicity. The main objective was to 
generate structure-activity relationships (SAR) that identify the key substructures that 
allow chalcone analogs to inhibit HSP60/10 biochemical functioning and selectively 
target colorectal cancer cells. Three sub-structures of typical chalcones – the α,β-
unsaturated ketone linker and the two aryl rings – were varied and evaluated in a panel 
of chaperonin-mediated biochemical assays and cell viability assays using cancerous 
and non-cancerous colon and intestine cells. While our results indicated that the linker 
 viii 
was highly important for generating potent inhibition in HSP60/10 biochemical assays 
and cell viability assays, we found that analogs bearing a 2-nitro substituent on the B-
ring were most selective for targeting cancer cells. While these lead compounds 
exhibited weak inhibition in a wound healing assay, they were nearly as equipotent in a 
clonogenic assay as they were in the cell viability assay.  
This study identified key SAR that allow chalcone analogs to inhibit the 
HSP60/10 chaperonin system and selectively target colorectal cancer cells. These 
findings will help future studies to optimize the pharmacological properties of this series 
of HSP60/10-targeting colorectal cancer chemotherapeutics. 
Steven M. Johnson, Ph.D., Chair 
 
 
 
 ix 
TABLE OF CONTENTS 
LIST OF TABLES ........................................................................................................... xi 
LIST OF FIGURES  ....................................................................................................... xii 
LIST OF SCHEMES ..................................................................................................... xiv 
LIST OF ABBREVIATIONS ........................................................................................... xv 
INTRODUCTION ............................................................................................................. 1 
Epidemiology of colorectal cancer ........................................................................ 1 
Histopathological classification, staging and treatment strategies ........................ 2 
Evolution of chemotherapy for colorectal cancer .................................................. 5 
 
Benefits and limitations of current therapeutics .................................................... 7 
 
Targeting Heat Shock Proteins (HSPs) in cancer ................................................. 8 
Successes and failures of previous HSP inhibitors ............................................... 8 
Structure and function of the human mitochondrial HSP60/10 chaperonin  
system ................................................................................................................. 9 
Role of HSP60 in cancer .................................................................................... 11 
Identifying HSP60/10 inhibitors .......................................................................... 12 
RESULTS AND DISCUSSION ...................................................................................... 16 
Evaluating the ability of chalcone analogs to inhibit the GroEL/ES and  
HSP60/10-mediated folding cycles .................................................................... 16 
 
Evaluating the ability of chalcone analogs to selectively kill cancerous  
over non-cancerous human cells ....................................................................... 19 
 
Evaluating chalcone lead analogs for their ability to inhibit colony formation  
of HCT 116 p53+/+ cells ...................................................................................... 23 
 
Evaluating lead chalcone analogs for their ability to inhibit in a wound  
healing assay using HCT 116 p53+/+ cells .......................................................... 25 
 
CONCLUSIONS AND FUTURE DIRECTIONS .............................................................. 29 
 
EXPERIMENTAL ........................................................................................................... 30 
 
General synthetic methods ................................................................................ 30 
 
 x 
General materials and methods for biochemical and cell-based experiments .... 39 
 
E. coli GroEL and GroES purification ................................................................. 39 
 
Human HSP60 purification ................................................................................. 41 
Human HSP10 purification ................................................................................. 42 
Evaluating compounds for inhibition in the GroEL/ES and HSP60/10-  
mediated dMDH refolding assays ...................................................................... 43 
 
Counter screening compounds for inhibition of native MDH enzymatic  
activity ................................................................................................................ 45 
 
Evaluating compounds for inhibition in the GroEL/ES-mediated dRho  
refolding assay ................................................................................................... 46 
 
Counter screening compounds for inhibition of native rhodanese enzymatic 
activity ................................................................................................................ 47 
 
Evaluating chalcones for effects on the viability of non-cancerous colon  
(FHC) and intestine (FHs-74 Int) cells, colorectal cancer cells  
(HCT 116 p53+/+ and p53-/-, DLD-1, HT-29) ........................................................ 48 
 
Evaluating chalcone lead analogs for their ability to inhibit colony formation  
HCT 116 p53+/+ cells .......................................................................................... 49 
 
Evaluating lead chalcone analogs for their ability to inhibit in a wound healing 
assay using HCT 116 p53+/+ cells....................................................................... 50 
 
Control compounds, calculation of I/E/CC50 values, and statistical  
considerations .................................................................................................... 51 
 
APPENDIX – SUPPLEMENTAL TABLES ..................................................................... 53 
 
REFERENCES .............................................................................................................. 55 
 
CURRICULUM VITAE  
 
 
 
 
 
 
  
 xi 
LIST OF TABLES 
Table 1 – Description regarding colorectal cancer staging ............................................... 3 
 
Table 2 – Examples of current FDA approved CRC therapeutics used clinically .............. 6 
 
Table 3 – Examples of current immunotherapy used for colorectal cancer ...................... 7 
 
Table 4 – IC50 biochemical assay results for chalcone analogs...................................... 18 
 
Table 5 – CC50 and EC50 cell viability results for chalcone analogs ................................ 20 
 
Table S4 – Log-transformed values ± SD of Table 4 biochemical assay results ............ 53 
 
Table S5 – Log-transformed values ± SD of Table 5 cell viability assay results ............. 54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 xii 
LIST OF FIGURES  
Figure 1 – Estimated colorectal cancer incidence and mortality worldwide in 2018.......... 1 
Figure 2 – Basic anatomy of colon and rectum ................................................................ 3 
Figure 3 – Stages involved in colorectal cancer ............................................................... 4 
Figure 4 – Evolution of chemotherapy for colorectal cancer patients ............................... 6 
Figure 5 – Five-year survival rates of patients with stage I-IV colorectal cancer .............. 8 
 
Figure 6 – Crystal structure of HSP60/10 ...................................................................... 10 
 
Figure 7 – General schematic of GroEL/ES and HSP60/10 refolding cycles .................. 10 
 
Figure 8 – Epolactaene and its derivative Lucilactaene ................................................. 12 
 
Figure 9 – Schematic representation of refolding assay used to evaluate the  
chalcones ...................................................................................................................... 13 
 
Figure 10A – Chalcone hits from our initial high throughput screening and  
secondary screening with their IC50 values for HSP60/10 .............................................. 14 
 
Figure 10B – Structure of the chalcone moiety .............................................................. 14 
 
Figure 10C – L2H17 chalcone derivative studied by Xu et al. for its  
chemo-preventive potential in colon cancer cells .......................................................... 14 
 
Figure 11A, B – Correlation plots representing E. coli GroEL/ES-mediated refolding  
and native assays for the MDH and Rho substrates ...................................................... 19 
 
Figure 11C – Correlation plot representing E. coli GroEL/ES and human HSP60/10-
mediated refolding assays ............................................................................................. 19 
 
Figure 12A – Correlation plot representing HCT 116 (p53+/+) cells vs FHC and  
FHs-74 Int ..................................................................................................................... 22 
 
Figure 12B – Correlation plot representing equipotent inhibition of HCT 116 (p53+/+) 
and p53-/- ....................................................................................................................... 22 
 
Figure 12C – Correlation plot representing the effects of chalcones in HT-29 and 
DLD-1 colorectal cancer cell lines .................................................................................. 22 
 
Figure 12D – Correlation plot representing HCT 116 (p53+/+) cells vs HSP60/10 
dMDH refolding ............................................................................................................. 22 
 
Figure 13 – Representation of clonogenic assay using HCT 116 p53+/+ cells and 
compound 19 (A) compound 20 (B) and compound 21 (C) ............................................ 24 
 
  
 xiii 
Figure 14 – Quantification of dose response analyses for compounds 19-21 tested  
in the HCT 116 p53+/+ clonogenicity assay ..................................................................... 24 
 
Figure 15A – Analysis of colony sizes for compound 21 tested in the clonogenicity  
assay ............................................................................................................................. 25 
 
Figure 15B – Typical colony size observed in DMSO treated well ................................. 25 
 
Figure 15C – Reduced colony size of a well containing 11µM of compound 21 ............. 25 
 
Figure 16 – Time course profile of wound closure for HCT 116 p53+/+ cells ................... 26 
 
Figure 17 – Determination of wound closure ................................................................. 26 
 
Figure 18 – Dose response analyses of compounds 19-21 tested in wound healing 
assay ............................................................................................................................. 27 
 
 
 xiv 
LIST OF SCHEMES 
Scheme 1 – General protocol for synthesizing chalcone analogs .................................. 16 
  
 xv 
LIST OF ABBREVIATIONS 
ADP  – Adenosine diphosphate 
AMP  – Adenosine monophosphate 
ATP  – Adenosine triphosphate 
CC50  – Cytotoxicity concentration for half-maximal signal in cell viability assays  
    using non-cancerous cells 
CH3CN  – Acetonitrile 
CRC          – Colorectal cancer 
DCM  – Dichloromethane 
DMSO  – Dimethyl sulphoxide 
Da  – Dalton  
EC50  – Effective concentration for half-maximal signal in cell viability assays using  
    colorectal cancer cells 
EDTA  – Ethylenediaminetetraacetic acid 
EtOAc – Ethyl acetate 
EtOH  – Ethanol 
HPLC  – High-performance liquid chromatography  
HSP  – Heat shock protein 
IC50  – Inhibitory concentration for half-maximal signal in biochemical assays 
IPTG  – Isopropyl β-D-1- thiogalactopyranoside 
kDa  – Kilodalton 
LB   – Luria Bertani broth 
MDH  – Malate dehydrogenase  
MEK  – Mitogen activated protein kinase enzyme 
MeOH  – Methanol 
MOA  – Mechanism of action 
MS  – Mass spectrometry  
NAD+  – Nicotinamide adenine dinucleotide (oxidized form) 
NADH  – Nicotinamide adenine dinucleotide (reduced form) 
NMR  – Nuclear magnetic resonance 
OD  – Optical density   
PBS  – Phosphate buffered saline 
PD-L1  – Programmed Death Ligand 
Rho  – Rhodanese  
SAR  – Structure activity relationship 
SDS PAGE – Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TFA  – Trifluoroacetic acid 
THF  – Tetrahydrofuran 
TNM  – Tumor, Node, Metastasis 
VEGF  – Vascular Endothelial Growth Factor 
WT  – Wild-type 
 
  
 
1
 
INTRODUCTION 
Epidemiology of colorectal cancer. 
Detailed accounts of colorectal cancer (CRC) incidence rates date back to the 1930s.1, 2 CRC ranks fourth in most commonly 
diagnosed malignancy among adults with a five-year survival rate of 65% for localized cancer and 10% for metastatic cancer.3 In 
2018, over 1.8 million cases of colorectal cancer were diagnosed worldwide, with 880,200 deaths reported (Figure 1). Unfortunately; 
CRC mortality is expected to rise by 60%, by 2030, thus emphasizing the need for better diagnosis and treatments for this disease.4-6 
 
Figure 1 – Estimated colorectal cancer incidence and mortality worldwide in 2018.7 
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Histopathological classification, staging and treatment strategies. 
The final portion of the gastro-intestinal tract is comprised of the ascending and 
descending colon. The entire colon spans five feet in length and joins the rectum, which 
is the last anatomic segment before the anus (Figure 2). Due to similar characteristics in 
the colon and rectum, cancers within these tissues are jointly referred to as “colorectal 
cancer”.8, 9  Typically, colorectal cancer begins as adenomatous polyps, which are 
benign growths lining the intestine and colon, and progresses to the cancerous stage as 
it acquires mutations.  Choice of treatment strategies are based on the extent of cancer 
progression, which is categorized by three primary staging systems (Table 1): (1) the 
Duke’s system; (2) the Astler- Coller system; and (3) the TNM (tumor, node, metastasis) 
system. The Duke’s system largely refers to rectal cancer and is comprised of Dukes A, 
B, C, and D stages. Stage A represents invasion, but not through the bowel wall, 
whereas B represents invasion through the bowel wall without affecting the lymph 
nodes. Stage C denotes invasion into the lymph nodes, and D represents distant 
metastasis. In 1954, another staging system, called the Astler-Coller staging system, 
was developed based on the Duke’s staging system. The Astler-Coller staging system 
consists of stage A, where tumors are limited to mucosa; stage B1, where tumors extend 
to the muscularis propria, but lymph nodes are not involved; stage B2, where tumors 
penetrate the muscularis propria; stage C1, where tumors extend into the muscularis 
propria with an invasion in lymph nodes; stage C2, where tumors have penetrated 
nearby lymph nodes; and stage D, where tumors have metastasized to distant organs.10-
12 The TNM system corresponds to local invasion and depth of tumor (T category), 
lymph nodes affected (N category), and the presence of distant metastasis (M category). 
 3 
 
Figure 2 – Basic anatomy of colon and rectum.13 This figure depicts the three major 
regions of the colon and final part of rectum. 
Table 1 – Description regarding colorectal cancer staging. This depicts Duke’s, Modified 
Astler-Coller (MAC), and TNM staging. TNM staging: primary tumor (T) is classified as 
Tis (tumor cannot be measured), T0 (main tumor cannot be found), and T1-T4 
representing increasing size and extent of the tumor; regional lymph nodes (N) classified 
as N0 (no cancer in nearby lymph nodes) and N1-N3 referring to the number and 
location of lymph nodes that cancer cells have spread to; and distant metastasis (M) 
classified as M0 (cancer has not spread to other body parts) and M1 (spread of cancer 
to other organs).14          
Stage Dukes MAC T N M 
0 - - Tis N0 M0 
I 
A A T1 N0 M0 
A B1 T2 N0 M0 
IIA B B2 T3 N0 M0 
IIB B B2 T4a N0 M0 
IIC B B3 T4b N0 M0 
IIIA 
C C1 T1-T2 N1/N1c M0 
C C1 T1 N2a M0 
IIIB 
C C2 T3-T4a N1/N1c M0 
C C1/C2 T2-T3 N2a M0 
C C1 T1-T2 N2b M0 
IIIC 
C C2 T4a N2a M0 
C C3 T3-T4a N2b M0 
IVA D D Ant T Any N M1a 
IVB D D Any T Any N M1b 
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Ultimately, the different systems are combined into a final staging system to 
decide treatment strategies (refer to Tables 1 & 2 and Figure 3).15 Stage 0 corresponds 
to non-cancerous growth termed as “polyp”, which is often treated by surgical removal 
(polypectomy). In stage I CRC, the now cancerous polyps, confined to the cell wall, are 
subjected to partial colectomy to remove the growths. In stage II, the tumors advance 
through the cell wall to adjacent tissues but have yet to invade the lymph nodes.  Stage 
III cancers start invading the lymph nodes but have not spread to distant organs in the 
body. Stage II and III cancers may involve combined treatment with surgery and adjunct 
chemotherapy involving the use of FOLFOX or Cape Ox. Finally, the stage IV CRC is 
the most aggressive and has spread to distant organs and tissues. Here, mostly 
chemotherapies with FOLFOX, Cape Ox, cetuximab, or irinotecan are used, which can 
be combined with radiation therapy.16 TNM staging has been approved by the American 
Joint Committee on Cancer and International Association of Cancer, and can be easily 
converted into the other classification systems.17  
 
 
Figure 3 – Stages involved in colorectal cancer. Stage 0 corresponds to polyp growth 
followed by stage I conversion of polyp to tumor and penetrance of the tumor to lymph 
node. Stage II and III represents tumor invading nearby blood vessels. Stage IV is the 
most aggressive form where tumors have spread (metastasized) to other organs.2 
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Evolution of chemotherapy for colorectal cancer.  
A) Small molecule inhibitors. 
Figure 4 depicts the overall evolution of chemotherapy for CRC. In the 1950’s, 
Heidelberger et al. first hypothesized that 5-FU could act as a DNA damaging agent by 
inhibiting the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine 
monophosphate (thymidylate).18 This process thereby accelerates the accumulation of 
dUMP, causing an imbalance in the nucleotide pool and resulting in DNA damage.19 
Another advancement in the chemotherapy of CRC was potentiation of 5-FU with 
leucovorin. Studies showed that in the presence of 20 µM leucovorin 5-FU was fivefold 
more cytotoxic in cultured leukemia cells.20 Following these findings, the anti-tumor 
activity of 5-FU/leucovorin was established in several studies.19 Introduction of the 
topoisomerase I inhibitor irinotecan, and the platinum containing agent oxaliplatin, was 
another critical development in the history of chemotherapy evolution (Table 2).21, 22 
Saltz et al. found that treatment with bolus 5-FU/leucovorin and irinotecan (IFL) resulted 
in significantly longer progression-free survival (7.0 vs 4.3 months), and longer overall 
survival (14.8 vs 12.6 months) than 5-FU/leucovorin alone as first-line therapy for 
patients with metastatic CRC.23 In the intergroup trial N9741, the efficacy of FOLFOX (5-
FU/leucovorin with oxaliplatin) was significantly better than IFL in relative to overall 
survival (19.5 vs 15.0 months).24 
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Figure 4 – Evolution of chemotherapy for colorectal cancer patients.19 
 
Table 2 – Examples of current FDA approved CRC therapeutics used clinically. 
 
 
B) Immunotherapy.  
Along with chemotherapy, immunotherapy also started to gain more attention. 
While Folman first proposed targeting angiogenesis as a potential anti-cancer strategy in 
1971,25 it was only after 2004 when the humanized monoclonal antibody bevacizumab, 
which acts by inhibiting vascular endothelial growth factor (VEGF), was evaluated.26 
Administration of bevacizumab significantly improved overall survival (20.3 vs 15.6 
months) and progression free survival (10.6 vs 6.2 months) compared to IFL alone. 
Drug Treatment Mechanism of Action FDA Approved Year
5-Fluorouracil Thymidylate synthase inhibitor 1962
Leucovorin Improves 5-FU cytotoxicity 2002
Irinotecan Topoisomerase inhibitor 2004
Oxaliplatin Inhibits DNA replication and transcription 2004
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Parallel studies were also focusing on targeting epidermal growth factor receptor 
(EGFR) as anti-cancer approach.27 The anti-cancer cetuximab and panitumumab were 
first approved agents of this class of therapeutics (Table 3).  
Table 3 – Examples of current immunotherapy used for colorectal cancer. 
 
Treatment Mechanism of Action FDA Approved Year 
Bevacizumab VEGF Antibody  2004 
Cetuximab EGFR Antibody 2004 
Panitumumab EGFR Antibody 2006 
 
Benefits and limitations of current therapeutics. 
Traditionally, surgical resection was the only option for curing colorectal cancer. 
However, adjuvant chemotherapy then started to show positive outcomes by 
administering 5-FU (5-fluorofuracil). Further, when combining 5-FU with leucovorin, the 
disease-free survival rate drastically improved as mentioned above. Since then, 
FOLFOX (folinic acid, leucovorin, fluorouracil, and oxaliplatin) became the standard 
treatment in colorectal cancer.28 On the other side, immunotherapy also developed that 
mainly functions in a targeted way to cancerous cells e.g., Cetuximab targets epidermal 
growth factor (EGFR), which gets overexpressed in malignant cells compared to normal 
cells.29  However, even with the efficacy of these anti-cancer therapeutics, there have 
been issues related to tumor adaptability leading to drug resistance. As a result, the five 
year survival rate in Stage IV colorectal cancer is just 11%, in contrast to a 92% survival 
rate in Stage I (Figure 5).16, 30 While a better understanding of the underlying drug 
resistance pathways is required, this dramatic decrease in patient survival, despite 
several therapeutics being available, highlights the urgency to develop novel 
therapeutics for CRC.  
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Figure 5 – Five-year survival rates of patients with stage I-IV colorectal cancer. 16 
Targeting Heat Shock Proteins (HSPs) in cancer. 
In an effort to identify new biological pathways to target for chemotherapeutic 
development, many researchers have explored a unique class of proteins, called 
molecular chaperones, or Heat Shock Proteins (HSPs), which maintain protein 
homeostasis in cells by helping other proteins fold to their functional states, or targeting 
them for degradation. Nomenclature for HSPs is based on the molecular weight (in kDa) 
of their primary subunits and are distinguished as small HSPs, HSP10, HSP40, HSP60 
HSP70, HSP90, and HSP100.31, 32 Increased expression levels of these molecular 
chaperones has been observed in various solid tumors and hematological malignancies, 
allowing cancer cells to evade apoptosis and continue to proliferate through largely 
unknown mechanisms.31  Despite significant efforts to target HSP90 and HSP70 as anti-
cancer strategies, so far there are no clinically approved chemotherapeutics targeting 
molecular chaperones.33 
Successes and failures of previous HSP inhibitors. 
HSP90 has about 200 client proteins, many of which have pro-survival roles and 
are associated with cancer progression.34 Substantial research efforts have been 
expended on identifying HSP90 inhibitors, which has led to the development of many 
compounds that have shown efficacy at inhibiting cancer cells in vitro (e.g. Radicicol, 
 9 
Benzoquinone, 17-AAG, Ansamycin, Geldanamycin).33 Unfortunately, many HSP90 
inhibitors failed in pre-clinical development due to number of reasons, including poor 
solubility, chemical instability, and general cytotoxicity.33 However, lead analogs that 
surmounted those challenges were largely ineffective in clinical trials owing to the fact 
that they would initiate a heat shock response in cancer cells, where other molecular 
chaperones (e.g. HSP70) get up-regulated to compensate for HSP90 inhibition.35 While 
HSP70 inhibitors are currently being discovered and developed as chemotherapeutic 
candidates (e.g. VER-155008 and Apoptozole), alone or in combination with HSP90 
inhibitors, none have yet progressed into clinical trials.33 While efforts continue to 
develop HSP90 and HSP70 inhibitors, another class of molecular chaperone, the 
HSP60/HSP10 chaperonin system, has gone largely unexplored.  
Structure and function of the human mitochondrial HSP60/10 chaperonin system. 
Most of the structural and functional information of the human HSP60/10 
chaperonin system has been elucidated from studying the prototypical chaperonin from 
Escherichia coli bacteria, called GroEL/ES. E.coli GroEL is highly homologous to human 
HSP60 (51% identity, 61% similarity) and a recent HSP60/10 crystal structure has 
further confirmed much of the structural homology between the two chaperonin systems 
(Figure 6).36 GroEL and HSP60 are 800 kDa, homotetradecameric complexes, 
comprised of two heptameric rings that are stacked back-to-back like a barrel.37-39 They 
function with their co-chaperones, called GroES and HSP10, which are heptamers that 
act as “lids” to cap off the GroEL and HSP60 rings, and this barrel with the lid offers a 
secluded environment for the unfolded polypeptide to fold (Figure 7). A schematic 
representation of this process is presented in Figure 7.  
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Figure 6 – Crystal structure of HSP60/10. A) HSP60 comprises of two rings that are 
stacked back-to-back. HSP60 works in conjunction with HSP10, forming a sequestered 
chamber wherein polypeptides can fold to their native, functional states. B) Top and 
bottom views of HSP60/10.36 
 
 
 
Figure 7 – General schematic of GroEL/ES and HSP60/10 refolding cycles. In healthy 
cells, nascent polypeptides traversing the mitochondrial membrane into the 
mitochondrial matrix bind to the apical domains of an empty HSP60 cis-ring (A). ATP 
binding to the cis-ring causes conformational movements of the HSP60 apical domains 
that allow HSP10 to cap off the barrel (B), releasing the polypeptide into the internal 
chamber where it is allowed to fold on its own, sequesters from the outside environment 
(C). ATP hydrolysis (C) signals the trans-HSP60 ring to bind additional polypeptide, 
ATP, and HSP10 (D-E), where the folding process begins anew. This folding cycle can 
then alternate between the two HSP60 rings.37-39 
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Role of HSP60 in cancer. 
Recent studies have begun illuminating distinct roles of HSP60 in tumorigenesis 
and progression.40, 41 For instance, studies have discovered that HSP60 can interact with 
proteins and pathways involved in cell transformation, angiogenesis, and metastasis, 
including HIF-1α, β-catenin, IKK/NF-κb, c-Myc, α3β1 integrin.42, 43 However, the exact 
role of HSP60 in cancer progression remains unknown. While HSP60 is upregulated in 
colon, prostrate, and cervical cancers, in other cancers it is downregulated or there is no 
change in expression levels.44  Thus, its role in cancer progression is confounding as it 
does not appear to merely be a response to an increased demand for molecular 
chaperones to maintain protein homeostasis in more rapidly dividing cells producing 
more proteins. Along with aberrant over-expression, accumulation of HSP60 in the 
cytosol has also been found to bind to and inactivate pro-caspase 3, thereby promoting 
anti-apoptotic effects.45 Studies in breast and colon adenocarcinoma cells have shown 
that inhibition of HSP60 on a genetic level leads to the disruption of HSP60 and p53 
association, which can release p53 and promote apoptosis.33, 46 In our recent studies, we 
found that HSP60 expression was elevated in small panel of colorectal cancer cells 
(HCT 116, HT-29, and DLD1) compared to non-cancerous FHC and FHs-74 Int cell lines 
(unpublished results).  Furthermore, we found that these colorectal cancer cells had a 
significant amount of HSP60 mis-localization to the cytosol. Consequently, we 
hypothesize that inhibiting cytosolic HSP60 with small molecules could allow us to 
selectively target cancer cells with minimal toxicity to non-cancer cells, where it is 
generally accepted that HSP60 resides only in the mitochondrial matrix, which is highly 
impermeable to penetration by exogeneous molecules.  
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Identifying HSP60/10 inhibitors. 
Compared to other heat shock proteins, identification of HSP60/10 has gone 
largely unexplored. In 2005, Nagumo et.al identified that epolactaene (Figure 8), a 
microbial metabolite isolated from Penicillium species, and a small panel of analogs 
inhibit HSP60 activity in vitro.47 With several potential electrophilic groups, it is not 
surprising that epolactaene was found to covalently modify the Cys442 residue of 
HSP60.47 While researchers found that epolactaene was cytotoxic to neuroblastoma 
cancer cells, no experiments were performed to determine whether this was from on-
target effects against HSP60/10. Another epolactaene derivative, lucilactaene, was 
found to be a cell cycle inhibitor that works in p53-dependent manner; however, its 
potential to target HSP60 has not been explored.48, 49 Furthermore, subsequent studies 
with epolactaene or any of its analogs have been lacking. This brings to an emergent 
need the identification of additional HSP60/10 inhibitors to investigate validating this 
chaperonin system as a viable chemotherapeutic target. 
 
Figure 8 – Epolactaene and its derivative Lucilactaene.  
 
Based on the principles of the GroEL/ES-mediated substrate polypeptide folding 
cycle, we recently reported the results from two high-throughput screens to identify 
GroEL/ES and HSP60/10 inhibitors (see Figure 9 for a schematic of the general 
GroEL/ES-dMDH and HSP60/10-dMDH refolding assays). In the first study, we 
screened a library of 700,000 structurally diverse small molecules and identified 235 hit 
GroEL/ES inhibitors.41 Follow-up studies on a sub-set of 22 of these identified that most 
were nearly equipotent against both E. coli GroEL/ES and human HSP60/10. In the 
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second study, we screened against a library of bioactive compounds that included 
known approved drugs and natural products, and identified 161 hit GroEL/ES inhibitors. 
Similar to the previous screening, follow-up re confirmation experiments showed that 
nearly all GroEL/ES inhibitors were equipotent against human HSP60/10.50 However, 
what was particularly interesting was that compounds based on a “chalcone” scaffold 
were highly represented among the hits (Figure 10A).  
 
 
Figure 9 – Schematic representation of refolding assay used to evaluate the chalcones. 
A) A binary complex of GroEL/ES is prepared followed by addition of denatured enzyme 
reporter. The refolding reaction is initiated by addition of ATP, then after a short 
incubation, the reaction is quenched by addition of EDTA. Inhibitors in this scheme are 
added at point A whereas for the native-counter screens, they are added at point B to 
determine false-positives that simply inhibit the reporter enzymes. Two substrates 
reporter enzymes are used: C) Malate dehydrogenase and D) Rhodanase.41 
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Figure 10A) Chalcone hits from our initial high throughput screening and secondary 
screening with their IC50 values for HSP60/10. B) Structure of the chalcone moiety.51 C) 
L2H17 chalcone derivative studied by Xu et al. for its chemo-preventive potential in 
colon cancer cells.52 
The term “chalcone” originates from the Greek word ‘chalco’, meaning ‘copper’, 
which is the color of many naturally occurring chalcone molecules.53 The core chalcone 
scaffold consists of an α,β-unsaturated ketone linking two aromatic rings (A and B-rings 
in Figure 10B)54 . While substituents and substitution patterns can vary on the aromatic 
ring across different naturally occurring chalcones, studies have indicated the α,β-
unsaturated ketone is usually important for the biological activity of chalcones.55 
Chalcones are naturally occurring compounds found in citrus fruits, apples, tomatoes, 
bean sprouts, potatoes and other plant species, such as Leguminosae, Asteraceae, and 
Moraceae.56, 57 The primary role of chalcones in plants is defense against pathogens, 
ultra violet radiation, and other reducing agents. The bioactivities of this diverse class of 
compounds is not only limited to plants, as they have played a significant role in human 
traditional medicines. Historically, chalcones had a major application in anti-allergy, anti-
ulcer, anti-tumor, anti-inflammatory, anti-bacterial, and anti-parasitic applications.58  A 
recent study conducted by Xu et al. evaluated the anti-cancer potential of a chalcone 
A
HSP60/10 IC50 :5.2 µM HSP60/10 IC50 :8.2 µM HSP60/10 IC50 :1.6 µM
HSP60/10 IC50 :1.29 µM HSP60/10 IC50 :1.34 µM HSP60/10 IC50 :1.20 µM
B C
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derivative L2H17 on colon cancer cells (Figure 10C). This study found that L2H17 
exhibited cytotoxic effects on colon cancer cells by activating G0/G1 cell cycle arrest and 
apoptosis. Furthermore, this study also demonstrated inhibition of migrative and invasive 
properties of cancer cells by interfering with Akt and NF-κB signaling.52  
Based on these findings, we hypothesize that chalcone-based HSP60/10 
inhibitors could be developed that will exhibit selective cytotoxicity to colorectal cancer 
cells over non-cancerous cells. However, before mounting an intensive drug 
development program towards this goal, the objective of this study was to generate 
structure-activity relationships that identified the key substructures that allow chalcone 
analogs to inhibit HSP60/10 biochemical functioning and selectively target colorectal 
cancer cells. Towards this goal, the three sub-structures of typical chalcones – the α,β-
unsaturated ketone linker and the two aryl rings – were varied in a small series of 
analogs, which we evaluated in a panel of chaperonin-mediated biochemical assays and 
cell viability assays using cancerous and non-cancerous colon and intestine cells.  
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RESULTS AND DISCUSSION 
Evaluating the ability of chalcone analogs to inhibit the GroEL/ES and HSP60/10-
mediated folding cycles. 
Extending from our previous studies that identified several chalcone-based 
inhibitors of human HSP60/10,50, 59, 60 we purchased and synthesized a small panel of 
additional analogs (see compounds 1-21 in Table 4 for structures) to identify the 
importance of the α,β-unsaturated ketone and the R1 and R2 substituents and 
substructures for generating potent and selective inhibition of HSP60/10 and colorectal 
cancer cells. A representative synthetic protocol is presented in Scheme 1, with 
complete compound characterization (1H-NMR, 13C-NMR, MS, and RP-HPLC) presented 
in the Experimental section. To obtain the amide-bearing analogs, intermediate amines 
10, 14, and 22 were synthesized via an Aldol condensation of 4-aminoacetophenone 
with the respective R2-aldehydes, then coupled with the respective R1-acid chlorides. 
Scheme 1 – General protocol for synthesizing chalcone analogs. (a) NaOH, H2O, MeOH, 
4 h at room temperature (10 = 91%; 14 = 80%; 22 = 61%); (b) R1-COCl, pyridine in DCM 
and/or THF for 4-18 h at room temperature (21-96% yields). 
 
 
After obtaining all the analogs, we first examined their efficacies at inhibiting E. 
coli GroEL/ES, as this enabled us to thoroughly probe for on-target effects at inhibiting 
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the chaperonin-mediated refolding cycle using two orthogonal reporter enzymes (Figure 
9), malate dehydrogenase (MDH) and rhodanese (Rho).  Using these two assays, we 
found that compounds were nearly equipotent at inhibiting GroEL/ES-mediated refolding 
of both the denatured MDH and Rho substrate reporter enzymes (Table 4 and Figure 
10). We then counter-screened compounds to identify potential false-positive hits that 
simply inhibited the enzymatic activity of the reporter MDH and Rho reporters. 
Gratifyingly, nearly all compounds were inactive against both reporter enzymes, except 
for compounds 5 and 10, which were only very weak inhibitors (Figure 10B). These 
results suggest that compounds were on-target for inhibiting the GroEL/ES-mediated 
substrate refolding cycles. As IC50 values for the analogs in the GroEL/ES-mediated 
dMDH and dRho refolding assays spanned over 3-orders of magnitude, from potent 
inhibition in the 1-10 µM range, to completely inactive (>100-250 µM), we examined for 
structure-activity relationships and found that the α,β-unsaturated ketone linker (4-21) 
was integral to inhibition, with the 2-nitro group on the B-ring (18-21) affording the most 
potent inhibitors.  
Knowing our compounds were on target for E. coli GroEL/ES, we next evaluated 
if they would also be able to inhibit the human HSP60/10 chaperonin system. The 
protocol was same as that for the E. coli GroEL/ES-dMDH refolding assay, only 
employing human HSP60/10 instead of GroEL/ES. This allowed us to directly compare 
results between the two chaperonin systems. As seen for the previously identified 
chalcones, we found that analogs were nearly equipotent against HSP60/10-mediated 
dMDH refolding compared with E. coli GroEL/ES (Table 4 and Figure 11A-C). While we 
were testing against the mitochondrial form of HSP60, where its 26 amino acid 
mitochondrial targeting sequence (MTS) has been removed, we anticipate these 
compounds will similarly inhibit naïve HSP60 (with the MTS) that would be in the cytosol 
of cancer cells; however, future studies will need to confirm this hypothesis. 
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Table 4 – IC50 biochemical assay results for chalcone analogs. Chalcone analogs 1-21 
were tested with E. coli GroEL/ES-mediated refolding assay with Rho and MDH 
substrates, and with human HSP60/10-mediated refolding with MDH as substrate.  
Results are also reported for the native MDH and Rho reporter counter-screens. Log 
transformed values are reported in appendix section - supplemental tables (S4 - S5).  
 
Rho MDH Rho MDH
1737 1 >100 >63 >250 >100 >100
1535 2 >100 >63 >250 >100 >100
1757 3 >100 >63 >250 >100 >100
1736 4 >100 >63 27 7.1 8.6
1292 5 40 >63 1.2 2.0 6.2
1512 6 >100 >63 61 20 21
1511 7 >100 >63 34 13 16
1514 8 >100 >63 39 20 21
1513 9 >100 >63 46 27 22
1282 10 55 46 12 5.9 9.8
1474 11 >100 >63 67 41 44
1305, 
1472
12 >100 >63 4.1 4.2 10
1473 13 >100 >63 37 21 20
1775 14 >100 >63 135 57 43
1477 15 >100 >63 40 9.4 14
1475 16 >100 >63 20 3.8 4.7
1476 17 >100 >63 27 4.3 5.9
1471 18 >100 >63 9.1 2.1 7.7
1290 19 >100 >63 2.5 0.73 2.5
1469 20 >100 >63 2.5 0.39 2.4
1470 21 >100 >63 5.5 0.79 2.3
Native Reporter 
Counter-Screens
GroEL/ES-mediated 
Refolding of:
Biochemical Assay IC50 (mM)
HSP60/10-dMDH 
Refolding
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Figure 11 – Correlation plots representing E. coli GroEL/ES-mediated refolding and 
native assays for the MDH and Rho substrates. Each data point represents an individual 
compound tested in the respective assays. A) The plot depicts equipotent IC50 values for 
both the refolding assays (Pearson correlation coefficient is 0.9345 (p-value <0.0001)), 
suggesting on-target inhibition of GroEL/ES. Blue color represents the three most potent 
GroEL/ES inhibitors (19-21). The gray zones indicate that IC50 values are higher than the 
maximum concentrations tested. B) Correlation plot representing compounds tested in 
the native reporter activity counter-screens. Only compounds 10 inhibits both native 
reporter activity and compound 5 inhibits only native Rho, but only weakly, further 
supporting on-target effects against the GroEL/ES-mediated refolding cycle. C) 
Correlation plot representing E. coli GroEL/ES and human HSP60/10-mediated refolding 
assays. This depicts compounds inhibiting the two chaperonins nearly equipotently 
(Pearson correlation coefficient 0.9736 (p-value <0.0001)). 
 
Evaluating the ability of chalcone analogs to selectively kill cancerous over non-
cancerous human cells. 
With a panel of compounds exhibiting striking SAR for inhibiting HSP60/10 
biochemical functioning, ranging from very potent to inactive, we next evaluated whether 
they would exhibit similar SAR for cytotoxicity against a small panel of cancerous and 
non-cancerous colorectal and intestinal cells in liquid culture. For this, we tested 
compounds for cytotoxicity against HCT 116 (p53+/+ and p53-/-), HT-29, and DLD-1 
colorectal cancer cells, and non-cancerous FHC (colon) and FHs-74 Int (intestine) cells, 
using a robust Alamar Blue-based cell viability assay protocol as we have previously 
reported (EC50 and CC50 results are presented in Table 5).50, 59, 60  
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Table 5 – CC50 and EC50 cell viability results for chalcone analogs. Compounds 1-21 
were tested in FHs-74 Int, FHC, HCT 116 p53+/+ & p53-/-, HT-29, and DLD-1 cell lines. 
When compounds 19-21 were tested against the colorectal cancer cells, the baseline of 
the dose-response curves for % cell viability did not go to zero but plateaued between 
~10-20% cell viability (i.e. ~80-90% inhibition), as indicated superscript “BP”. The color 
scheme on right denotes fold selectivity of HCT 116 p53+/+ cells vs FHs-74 Int and FHC 
cells, with red indicating the lowest selectivity and blue indicating higher fold selectivity to 
non-cancer cells. 
 
p53+/+ p53-/- 
1737 1 >100 >100 >100 >100 >100 >100 N/A N/A
1535 2 >100 >100 >100 >100 >100 >100 N/A N/A
1757 3 >100 >100 >100 >100 >100 >100 N/A N/A
1736 4 36 71 9.5 11 25 14 3.8 7.5
1292 5 12 28 5.8 6.1 9.6 8.2 2.1 4.8
1512 6 69 82 20 21 34 30 3.5 4.1
1511 7 34 82 16 17 35 23 2.1 5.1
1514 8 >100 100 32 32 51 39 3.1 3.1
1513 9 80 99 22 30 52 32 3.6 4.5
1282 10 61 90 21 24 31 28 2.9 4.3
1474 11 84 >100 56 72 84 88 1.5 1.8
1305, 
1472
12 77 87 40 53 60 54 1.9 2.2
1473 13 97 >100 42 59 69 76 2.3 2.4
1775 14 90 >100 27 23 33 35 3.3 3.7
1477 15 37 86 11 11 28 13 3.4 7.8
1475 16 25 83 12 16 35 28 2.0 6.6
1476 17 67 73 17 28 46 36 3.9 4.3
1471 18 10 18 1.7 1.8 6.3 2.0 6.1 11
1290 19 >100 >100 3.3BP 4.1BP 31 2.8BP 30 30
1469 20 39 69 2.6 2.5 11BP 2.4BP 15 27
1470 21 >100 >100 4.1BP 25BP >100 4.5BP 24 24
Cell Viability EC50 (mM)
HT-29
FHS-74Int 
(Instestine)
FHC 
(Colon)
Colon Cancer Cells Fold HCT 116 p53+/+ vsNon-Cancer Cells
FHS-74Int 
(Instestine)
FHC 
(Colon)
DLD-1
HCT 116
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We were excited to see that many compounds exhibited selective cytotoxicity to 
the HCT 116 (p53+/+) colon cancer cells over the non-cancerous FHC colon and FHs-74 
Int intestine cells; although, for reasons that are unknown, compounds were generally 
more cytotoxic against the FHs-74 Int intestine cells compared to the FHC colon cells 
(Figure 12A). In accordance with our biochemical results, compounds lacking the α,β-
unsaturated ketone linker were inactive against both cancerous and non-cancerous 
cells. What was most impressive was that the 2-nitro bearing analogs, in particular 
compounds 19-21, exhibited the highest selectivity (15-30-fold) for the colon cancer cells 
over non-cancerous colon and intestine cells. However, something that we noted during 
testing of compound 19-21 was that the baselines of the dose-response curves for % 
cell viability did not go to 0% at the highest compound concentrations, but plateaued 
between ~10-20% (as indicated by the superscript “BP” notations in the EC50 results in 
Table 5). This suggests that cancer cells may need to be exposed for >48 h with these 
compounds for complete cytotoxicity effects to be realized. 
As a previous study had indicated a possible role for HSP60 interacting with p53, 
we wanted to evaluate whether or not our HSP60/10 inhibitors would exhibit variable 
effects against p53-null cells.46 Many colorectal cancers have developed ways to evade 
p53-mediated apoptosis mechanisms, either by expressing mutated, non-functional 
variants or not expressing p53 at all, and thus it would be detrimental to our 
chemotherapeutic strategy if HSP60/10 inhibitors were p53-dependent. To determine 
this possibility, we evaluated compounds against the isogenic HCT 116 p53-/- cell line 
and found a nearly 1:1 correlation when compared to the HCT 116 p53+/+ (Figure 12B), 
thus indicating that inhibitor effects are independent of p53 status. This result suggests 
our HSP60/10-targeting chemotherapeutic strategy should be effective against cancer 
cells that have become resistant to current chemotherapeutics through such a 
mechanism. We next evaluated against two additional colorectal cancer cell lines, the 
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HT-29 and DLD-1 cell lines, to ensure that inhibitor effects were not simply inherent to 
HCT 116 cells. As observed in Figure 12C, there is a high correlation for inhibitor 
cytotoxicity to both HT-29 and DLD-1 cell lines compare to the HCT 116 p53+/+ cells; 
however, lead candidates 19-21 were less effective against the DLD-1 cells. The 
reasons for this divergence in efficacy remain unknown and would benefit from further 
investigation. Further studies should also expand to a larger set of colorectal cancer 
cells to determine broader spectrum effects. 
 
 
Figure 12A) Correlation plot representing HCT 116 (p53+/+) cells vs FHC and FHs-74 Int. 
Compounds are selectively cytotoxic to HCT 116 (p53+/+) colon cancer cells over non-
cancerous FHC and FHs-74 Int cells. B) Correlation plot representing equipotent 
inhibition of HCT 116 (p53+/+) and p53-/-.This indicates cytotoxicity is p53 independent 
(Pearson correlation co-efficient is 0.9489 (p-value <0.0001). C) Correlation plot 
representing the effects of chalcones in HT-29 and DLD-1 colorectal cancer cell lines. 
Pearson correlation of HCT 116 p53+/+ vs HT-29 is 0.9801 (p-value <0.0001) and with 
DLD-1 is 0.7716 (p-value <0.0001). D) Correlation plot representing HCT 116 (p53+/+) 
cells vs HSP60/10 dMDH refolding. A high Pearson correlation of 0.8785 (p-value 
<0.0001) is observed between compounds inhibiting HSP60/10 and HCT 116 (p53+/+) 
cells, which supports possible on-target effects in cells. 
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What was perhaps the most exciting result of this study was that we found a high 
correlation between compounds exhibiting cytotoxicity to HCT 116 (p53+/+) cells and 
inhibiting HSP60/10-folding capabilities in vitro (Figure 12D).  While this supports that 
compounds could be functioning on-target against HSP60/10 in cells, further studies are 
warranted to conclusively determine inhibitor mechanisms of action. For example, we 
would like to identify inhibitor binding sites and develop point mutations that prevent 
inhibitors from binding to HSP60, which could be expressed in colorectal cancer cells to 
see if any EC50 shifts occur. Furthermore, we would like to develop molecular probes for 
affinity pull-down experiments to see what other proteins might be identified as targets.  
Evaluating chalcone lead analogs for their ability to inhibit colony formation of HCT 
116 p53+/+ cells.   
As compounds 19-21 were our most potent HSP60 inhibitors with the highest 
selective cytotoxicity to colon cancer over non-cancerous cells, we focused on these 
three analogs and evaluated their ability to inhibit colony formation of HCT 116 p53+/+ 
colorectal cancer cells. This in vitro assay examines the ability of individual cancer cells 
to survive inhibitor treatment, then grow into colonies in the absence of compounds. A 
detailed protocol for this assay is presented in the Experimental section. Briefly, in this 
assay, cancer cells are seeded at 500 cells per well and treated with compounds for 72 
hours. Then, the wells were replaced with fresh media without any compounds, and the 
cells were incubated for a further 7 days, then fixed on day 11 and stained with crystal 
violet dye.61 Upon treating HCT 116 p53+/+ cells with compounds 19-21, the fractions of 
surviving colonies were determined for each of the compounds. Plates were imaged and 
colonies were manually counted for each well. Representative images for individual 
experiments for compounds 19-21 are shown in Figure 13, with data from replicate 
analyses graphed in the panels in Figure 14. Perhaps not surprisingly, we found similar 
EC50 values in this assay as we had found in the Alamar Blue-based cell viability assays 
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(Figure 14). While the dose-response baseline for compound 21 plateaued at ~15% (as 
noted to occur in the cell viability assay), there were no surviving colonies found at the 
higher concentrations of compounds 19 & 20, suggesting they are faster-acting cytotoxic 
agents than is compound 21. However, even though viable colonies were present at the 
higher concentrations of compound 21, we noted a significant reduction in their sizes, as 
quantified using ImageJ software (Figure 15).   
 
Figure 13 – Representation of clonogenic assay using HCT 116 p53+/+ cells and 
compound 19 (A) compound 20 (B) and compound 21 (C).  DMSO is used as control 
and increasing concentration results in decreasing numbers and sizes of colonies.  
 
 
 
Figure 14 – Quantitation of dose response analyses for compounds 19-21 tested in the 
HCT 116 p53+/+ clonogenicity assay. (EC50 values are 0.60, 0.67, and 0.58 µM for 19, 
20, and 21, respectively)  
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Figure 15A) Analysis of colony sizes for compound 21 tested in the clonogenicity assay. 
The size of colonies decreases as compound concentration increases. B) Typical colony 
size observed in DMSO treated well. C) Reduced colony size of a well containing 11 µM 
of compound 21. Images were captured with a Nikon camera attached to a Zeiss 
Axiovert 200 inverted microscope.  
 
Evaluating lead chalcone analogs for their ability to inhibit in a wound healing assay 
using HCT 116 p53+/+ cells. 
Another hallmark of cancer is migrating to distant sites from the source of primary 
tumor. Therefore, we evaluated the effects of compounds 19-21 at inhibiting the 
migratory capacity of HCT 116 p53+/+ colorectal cancer cells using a wound healing 
assay. A detailed protocol for this assay is presented in the Experimental section. Briefly, 
cells were seeded in 96-well plates and cultured to 80% confluence, then a “wound” was 
introduced using a 96-well wound making tool. Test compounds were then added and 
plates were incubated for 32 hours in an Incucyte system, while monitoring the wound 
closure with real-time imaging.62 While time-lapse data was obtained for each 
compound, to simplify data analysis and presentation, we chose to determine percent 
wound closure at the 26 hour time point, when 90% of the wound had closed in vehicle 
control treated wells (Figure 16).  
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Figure 16 – Time course profile of wound closure for HCT 116 p53+/+ cells. 90% wound 
closure for the DMSO vehicle treated wells occurred by ~26 hours. 
 
Figure 17 – Determination of wound closure. The Incucyte software offers an automated 
way to calculated % wound closure where the user can choose different colors to identify 
wound and confluent cells. Panel A depicts a well with 0.13 µM compound 20, where the 
software detected wound and cells at t = 0 and 26 hours (left and right images, 
respectively). As compounds 19-21 precipitated at higher concentrations, the software 
was unable to differentiate the wound from the cells, as shown in panel B images of a 
well with 100 µM of compound 21. To overcome this problem, all the wells were 
manually counted using ImageJ software. Panel C depicts a well with 0.13 µM of 
compound 20, and the wound was counted manually by measuring five distance as 
shown in the t = 0 and 26 hour images. Panel D depicts a well with 100 µM of compound 
21, where the wound can be easily viewed and measured at both the time points. 
 27 
When analyzing data for the compounds 19-21, we unfortunately found that at 
the highest compound concentrations (33 and 100 µM), compound precipitation 
prevented the Incucyte software from being able to process the images in an automated 
manner (Figure 17A & B). To overcome this problem, we manually counted the wound 
distances for all the compounds using ImageJ software (Figure 17C & D). Five distances 
were measured manually for each well at both 0 and 26 hours, and percent wound 
closures were determined as an average of these five distance measurements. Results 
from the replicate analyses for compounds 19-21 are presented in Figure 18.  
 
Figure 18 – Dose response analyses of compounds 19-21 tested in wound healing 
assay. Compounds exhibit weaker wound healing inhibition, with compound 20 
exhibiting the greatest potency (EC50 values are 59, 13, and >100 µM for 19, 20, and 21, 
respectively).  
 
Interestingly, EC50 values determined for each compound in this wound healing 
assay were considerably higher than those determined in the cell viability and 
clonogenicity assays discussed above. This is putatively because compounds were 
incubated with cells over a much shorter duration in the wound healing assay (26 hours) 
compared to the cell viability (48 hours) and clonogenicity (72 hours) assays, suggesting 
that compound cytotoxicity is largely occurring within the 24-72-hour window. Compound 
20 exhibited the most potent inhibition of wound healing (EC50 = 13 µM) and, coupled 
with inhibition results from the HSP60/10 refolding, cell viability, and clonogenicity 
 28 
assays, highlight it as the standout lead chemotherapeutic candidate in this study. 
However, future studies are warranted to further optimize the chemotherapeutic potential 
of this inhibitor series. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
To summarize our findings from this study, we developed a small library of 21 
compounds based on a chalcone scaffold, where we varied the α,β-unsaturated ketone 
and the R1 and R2 substituents and substructures to identify what groups were important 
for generating potent and selective inhibition of HSP60/10 and colorectal cancer cells. 
While our results indicated that the α,β-unsaturated ketone was highly important for 
generating potent inhibition in HSP60/10 biochemical assays and cell viability assays, 
we found that analogs bearing a 2-nitro substituent on the B-ring (compounds 19-21) 
were most selective for targeting colorectal cancer cells over non-cancerous colon and 
intestine cells. We further tested these three lead analogs in a clonogenicity assay, 
where we found they had nearly equipotent inhibition as in the Alamar Blue cell viability 
assay. As cell invasion and migration is an important hallmark of cancer, we further 
tested these compounds to inhibit the migratory capacity of colorectal cancer cells in a 
wound healing assay. To our surprise, these compounds exhibited weaker inhibitory 
effects than the in the cell viability and clonogenicity assays, suggesting that a higher 
duration of exposure time is necessary for inhibitors to fully exert their cytotoxic potential. 
Importantly, this study identified key structure-activity relationships that allow chalcone 
analogs to inhibit the human HSP60/10 chaperonin system and selectively target 
colorectal cancer cells over non-cancerous cells. These findings will help guide future 
studies to more efficiently optimize the pharmacological properties of this series of 
HSP60/10-targeting colorectal cancer chemotherapeutic candidates. In addition, while a 
correlation was evident between compounds inhibiting in the HSP60/10-mediated dMDH 
refolding assay and the colorectal cancer cell viability assays, additional studies will 
need to be conducted to more conclusively determine whether or not inhibitors are 
acting on-target against HSP60/10 inside cancer cells. 
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EXPERIMENTAL 
General synthetic methods.  
Unless otherwise stated, all chemicals were purchased from commercial 
suppliers and used without further purification.  Reaction progress was monitored by 
thin-layer chromatography on silica gel 60 F254 coated glass plates (EM Sciences).  
Flash chromatography was performed using a Biotage Isolera One flash 
chromatography system and eluting through Biotage KP-Sil Zip or Snap silica gel 
columns for normal-phase separations (hexanes:EtOAc gradients), or Snap KP-C18-HS 
columns for reverse-phase separations (H2O:MeOH gradients).  Reverse-phase high-
performance liquid chromatography (RP-HPLC) was performed using a Waters 1525 
binary pump, 2489 tunable UV/Vis detector (254 and 280 nm detection), and 2707 
autosampler.  For preparatory HPLC purification, samples were chromatographically 
separated using a Waters XSelect CSH C18 OBD prep column (part number 
186005422, 130 Å pore size, 5 µm particle size, 19x150 mm), eluting with a H2O:CH3CN 
gradient solvent system.  Linear gradients were run from either 100:0, 80:20, or 60:40 
A:B to 0:100 A:B (A = 95:5 H2O:CH3CN, 0.05% TFA; B = 5:95 H2O:CH3CN, 0.05% TFA.  
Products from normal-phase separations were concentrated directly, and reverse-phase 
separations were concentrated, diluted with H2O, frozen, and lyophilized.  For primary 
compound purity analyses (HPLC-1), samples were chromatographically separated 
using a Waters XSelect CSH C18 column (part number 186005282, 130 Å pore size, 5 
µm particle size, 3.0x150 mm), eluting with the above H2O:CH3CN gradient solvent 
systems.  For secondary purity analyses (HPLC-2) of final test compounds, samples 
were chromatographically separated using a Waters XBridge C18 column (either part 
number 186003027, 130 Å pore size, 3.5 µm particle size, 3.0x100 mm, or part number 
186003132, 130 Å pore size, 5.0 µm particle size, 3.0x100 mm), eluting with a 
H2O:MeOH gradient solvent system.  Linear gradients were run from either 100:0, 80:20, 
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60:40, or 20:80 A:B to 0:100 A:B (A = 95:5 H2O:MeOH, 0.05% TFA; B = 5:95 
H2O:MeOH, 0.05% TFA).  Test compounds were found to be >95% in purity from both 
RP-HPLC analyses, with the exception of 15, 16, and 21, which were found to be >93-
94% pure.  Mass spectrometry data were collected using either an Agilent LC 1200-MS 
6130 (lo-res) or Agilent LC 1290-MS 6545 Q-TOF (hi-res) analytical LC-MS at the IU 
Chemical Genomics Core Facility (CGCF).  1H- and 13C-NMR spectra were recorded on 
a Bruker 300 MHz spectrometer at the IU CGCF.  Chemical shifts are reported in parts 
per million and calibrated to the d6-DMSO solvent peaks at 2.50 and 39.51 ppm, 
respectively. 
 .......................................................................................................................................... 
(E)-1-(4-aminophenyl)-3-(furan-2-yl)prop-2-en-1-one (10).   
 
Sodium hydroxide (3.02 g, 75.5 mmol) was added to a stirring mixture of 2-furaldehyde 
(0.35 mL, 4.2 mmol) and 4-aminoacetophenone (511 mg, 3.78 mmol) in 2:1 EtOH:H2O 
(21 mL), and the reaction was left to stir at room temperature.  After 4 h, the reaction 
was diluted with water, neutralized with 1 M HCl, and the precipitate was filtered, rinsed 
with water, and collected.  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 10 as a yellow solid (731 mg, 91% yield).  An aliquot of compound was further 
purified by preparatory RP-HPLC (H2O:CH3CN gradient), concentrated, and lyophilized 
to a powder for testing.  1H-NMR (300 MHz, d6-DMSO) δ 7.80-7.87 (m, 3H), 7.40-7.55 
(m, 2H), 7.00 (d, J = 3.4 Hz, 1H), 6.65 (dd, J = 3.4, 1.8 Hz, 1H), 6.57-6.64 (m, 2H), 6.17 
(s, 2H); 13C-NMR (75 MHz, d6-DMSO) δ 185.23, 153.91, 151.52, 145.44, 130.90, 
128.26, 125.15, 119.25, 115.42, 112.87, 112.80; MS (Q-TOF ESI) C13H12NO2 [MH]+ m/z 
expected = 214.0863, observed = 214.1121; HPLC-1 = 95%; HPLC-2 = 96%. 
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 .......................................................................................................................................... 
 (E)-N-(4-(3-(furan-2-yl)acryloyl)phenyl)acetamide (11).   
 
Pyridine (65.5 μL, 0.803 mmol) was added to a stirring mixture of 10 (142 mg, 0.667 
mmol) and acetyl chloride (52.5 μL, 0.736 mmol1 in anhydrous dichloromethane (5 mL), 
and the reaction was left to stir at room temperature (under Ar).  After 18 h, flash 
chromatographic purification (hexanes:EtOAc gradient) afforded 11 as a yellow solid 
(163 mg, 96% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.32 (s, 1H), 8.01-8.09 (m, 2H), 
7.91 (d, J = 1.6 Hz, 1H), 7.72-7.79 (m, 2H), 7.54 (s, 2H), 7.09 (dd, J = 3.4, 0.7 Hz, 1H), 
6.69 (dd, J = 3.4, 1.8 Hz, 1H), 2.09 (s, 3H); 13C-NMR (75 MHz, d6-DMSO) δ 186.95, 
169.01, 151.25, 146.09, 143.73, 132.03, 129.92, 129.71, 118.65, 118.37, 116.78, 
113.13, 24.23; MS (Q-TOF ESI) C15H12NO3 [M-H]- m/z expected = 254.0823, observed = 
254.0825; HPLC-1 = 96%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
 (E)-N-(4-(3-(furan-2-yl)acryloyl)phenyl)thiophene-2-carboxamide (12).   
 
Pyridine (42.5 μL, 0.521 mmol) was added to a stirring mixture of 10 (92.5 mg, 0.434 
mmol) and thiophene-2-carbonyl chloride (51.0 μL, 0.477 mmol) in anhydrous 
dichloromethane (5 mL), and the reaction was left to stir at room temperature (under Ar).  
After 18 h, flash chromatographic purification (hexanes:EtOAc gradient) afforded 12 as a 
yellow solid (117 mg, 84% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.55 (s, 1H), 8.07-
8.15 (m, 3H), 7.89-7.98 (m, 4H), 7.58 (s, 2H), 7.25 (dd, J = 5.0, 3.8 Hz, 1H), 7.10 (dd, J 
= 3.4, 0.6 Hz, 1H), 6.69 (dd, J = 3.4, 1.8 Hz, 1H); 13C-NMR (75 MHz, d6-DMSO) δ 
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187.04, 160.24, 151.25, 146.12, 143.28, 139.53, 132.62, 132.57, 130.03, 129.81, 
129.58, 128.23, 119.59, 118.66, 116.83, 113.14; MS (Q-TOF ESI) C18H12NO3S [M-H]- 
m/z expected = 322.0543, observed = 322.0522; HPLC-1 = 98%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
 (E)-N-(4-(3-(furan-2-yl)acryloyl)phenyl)benzamide (13).   
 
Pyridine (37.5 μL, 0.460 mmol) was added to a stirring mixture of 10 (81.8 mg, 0.384 
mmol) and benzoyl chloride (59.5 μL, 0.516 mmol) in anhydrous dichloromethane (5 
mL), and the reaction was left to stir at room temperature (under Ar).  After 18 h, flash 
chromatographic purification (hexanes:EtOAc gradient) afforded 13 as a yellow-orange 
solid (88.2 mg, 72% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.61 (s, 1H), 8.08-8.16 (m, 
2H), 7.95-8.04 (m, 4H), 7.92 (d, J = 1.5 Hz, 1H), 7.51-7.66 (m, 5H), 7.11 (dd, J = 3.4, 0.7 
Hz, 1H), (6.70 (dd, J = 3.4, 1.8 Hz, 1H); 13C-NMR (75 MHz, d6-DMSO) δ 187.06, 166.04, 
151.26, 146.12, 143.70, 134.59, 132.54, 131.94, 130.02, 129.53, 128.49, 127.84, 
119.63, 118.68, 116.83, 113.14; MS (Q-TOF ESI) C20H14NO3 [M-H]- m/z expected = 
316.0979, observed = 316.0992; HPLC-1 = 95%; HPLC-2 = 96%. 
 .......................................................................................................................................... 
(E)-1-(4-aminophenyl)-3-phenylprop-2-en-1-one (14).   
 
Sodium hydroxide (2.70 g, 67.5 mmol) was added to a stirring mixture of benzaldehyde 
(0.33 mL, 3.3 mmol) and 4-aminoacetophenone (397 mg, 2.94 mmol) in 2:1 EtOH:H2O 
(15 mL), and the reaction was left to stir at room temperature.  After 4 h, the reaction 
was diluted with water, neutralized with 1 M HCl, and the precipitate was filtered, rinsed 
 34 
with water, and collected.  Flash chromatographic purification (hexanes:EtOAc gradient) 
afforded 14 as a yellow solid (524 mg, 80% yield).  An aliquot of compound was further 
purified by preparatory RP-HPLC (H2O:CH3CN gradient), concentrated, and lyophilized 
to a powder for testing.  1H-NMR (300 MHz, d6-DMSO) δ 7.91-7.97 (m, 2H), 7.80-7.90 
(m, 3H), 7.57-7.66 (m, 1H), 7.39-7.48 (m, 3H), 6.59-6.67 (m, 2H), 4.99 (br s, 2H); 13C-
NMR (75 MHz, d6-DMSO) δ 185.86, 153.66, 141.42, 135.13, 131.12, 129.98, 128.83, 
128.49, 125.42, 122.38, 112.85; MS (Q-TOF ESI) C15H14NO [MH]+ m/z expected = 
224.1070, observed = 224.1050; HPLC-1 = 95%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
N-(4-cinnamoylphenyl)acetamide (15).   
 
Pyridine (46.0 μL, 0.564 mmol) was added to a stirring mixture of 14 (105 mg, 0.472 
mmol) and acetyl chloride (40.0 μL, 0.561 mmol) in anhydrous THF (5 mL), and the 
reaction was left to stir at room temperature (under Ar).  After 18 h, flash 
chromatographic purification (hexanes:EtOAc gradient), followed by preparatory RP-
HPLC purification (H2O:CH3CN gradient), afforded 15 as a yellow solid (83.3 mg, 67% 
yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.33 (s, 1H), 8.11-8.18 (m, 2H), 7.90-7.98 (m, 
1H), 7.85-7.89 (m, 2H), 7.75-7.80 (m, 2H), 7.68-7.75 (m, 1H), 7.42-7.49 (m, 3H), 2.10 (s, 
3H); 13C-NMR (75 MHz, d6-DMSO) δ 187.51, 169.01, 143.78, 143.32, 134.80, 132.10, 
130.51, 129.94, 128.93, 128.82, 121.98, 118.29, 24.23; MS (Q-TOF ESI) C17H14NO2 [M-
H]- m/z expected = 264.1030, observed = 264.1037; HPLC-1 = 96%; HPLC-2 = 94%. 
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 .......................................................................................................................................... 
N-(4-cinnamoylphenyl)thiophene-2-carboxamide (16).   
 
Pyridine (44.0 μL, 0.540 mmol) was added to a stirring mixture of 14 (99.2 mg, 0.444 
mmol) and thiophene-2-carbonyl chloride (57.0 μL, 0.533 mmol) in anhydrous THF (5 
mL), and the reaction was left to stir at room temperature (under Ar).  After 18 h, flash 
chromatographic purification (hexanes:EtOAc gradient), followed by preparatory RP-
HPLC purification (H2O:CH3CN gradient), afforded 16 as a yellow solid (96.0 mg, 65% 
yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.56 (s, 1H), 8.21 (d, J = 8.8 Hz, 2H), 8.10 (dd, 
J = 3.7, 1.0 Hz, 1H), 7.87-8.02 (m, 6H), 7.70-7.78 (m, 1H), 7.43-7.50 (m, 3H), 7.26 (dd, J 
= 4.9, 3.8 Hz, 1H); 13C-NMR (75 MHz, d6-DMSO) δ 187.60, 160.25, 143.47, 143.34, 
139.53, 134.79, 132.63, 130.54, 129.81, 128.93, 128.85, 128.23, 121.97, 119.52; MS 
(Q-TOF ESI) C20H14NO2S [M-H]- m/z expected = 332.0751, observed = 332.0728; 
HPLC-1 = 93%; HPLC-2 = 95%. 
 .......................................................................................................................................... 
N-(4-cinnamoylphenyl)benzamide (17).   
 
Pyridine (37.0 μL, 0.454 mmol) was added to a stirring mixture of 14 (85.1 mg, 0.381 
mmol) and benzoyl chloride (53.0 μL, 0.460 mmol) in anhydrous THF (5 mL), and the 
reaction was left to stir at room temperature (under Ar).  After 18 h, flash 
chromatographic purification (hexanes:EtOAc gradient), followed by preparatory RP-
HPLC purification (H2O:CH3CN gradient), afforded 17 as a yellow solid (61.6 mg, 50% 
yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.61 (s, 1H), 8.18-8.26 (m, 2H), 7.95-8.05 (m, 
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5H), 7.87-7.93 (m, 2H), 7.70-7.79 (m, 1H), 7.52-7.66 (m, 3H), 7.43-7.50 (m, 3H); 13C-
NMR (75 MHz, d6-DMSO) δ 187.63, 166.06, 143.77, 143.46, 134.80, 134.59, 132.62, 
131.96, 130.55, 129.78, 128.94, 128.86, 128.50, 127.84, 122.00, 119.57; MS (Q-TOF 
ESI) C22H16NO2 [M-H]- m/z expected = 326.1187, observed = 326.1199; HPLC-1 = 96%; 
HPLC-2 = 97%. 
 .......................................................................................................................................... 
(E)-1-(4-aminophenyl)-3-(3-nitrophenyl)prop-2-en-1-one (22).   
 
Sodium hydroxide (3.29 g, 82.3 mmol) was added to a stirring mixture of 3-
nitrobenzaldehyde (669 mg, 4.43 mmol) and 4-aminoacetophenone (565 mg, 4.18 mmol) 
in 2:1 EtOH:H2O (21 mL), and the reaction was left to stir at room temperature.  After 4 h, 
the reaction was diluted with water and the precipitate was filtered, rinsed with water, and 
collected.  Flash chromatographic purification (hexanes:EtOAc gradient) afforded 22 as a 
yellow solid (689 mg, 61% yield).  1H-NMR (300 MHz, d6-DMSO) δ 8.72 (s, 1H), 8.29 (d, 
J = 7.7 Hz, 1H), 8.19-8.26 (m, 1H), 8.09 (d, J = 15.6 Hz, 1H), 7.94-8.02 (m, 2H), 7.66-7.77 
(m, 2H), 6.59-6.68 (m, 2H), 6.23 (s, 2H); 13C-NMR (75 MHz, d6-DMSO) δ 185.55, 154.18, 
148.45, 138.93, 137.14, 134.83, 131.44, 130.28, 125.32, 125.04, 124.12, 122.63, 112.73; 
MS (ESI) C15H13N2O3 [MH]+ m/z expected = 269.1, observed = 269.0; HPLC-1 = 95%. 
 .......................................................................................................................................... 
 (E)-N-(4-(3-(3-nitrophenyl)acryloyl)phenyl)acetamide (18).   
 
Pyridine (41.0 μL, 0.503 mmol) was added to a stirring mixture of 22 (112 mg, 0.417 
mmol) and acetyl chloride (33.0 μL, 0.462 mmol) in anhydrous dichloromethane (5 mL) 
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and THF (5 mL), and the reaction was left to stir at room temperature (under Ar).  After 
18 h, flash chromatographic purification (hexanes:EtOAc gradient) afforded 18 as a 
yellow solid (88.3 mg, 68% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.34 (s, 1H), 8.77 
(t, J = 1.9 Hz, 1H), 8.32 (d, J = 7.8 Hz, 1H), 8.26 (ddd, J = 8.2, 2.2, 0.8 Hz, 1H), 8.12-
8.22 (m, 3H), 7.71-7.86 (m, 4H), 2.10 (s, 3H); 13C-NMR (75 MHz, d6-DMSO) δ 187.33, 
169.05, 148.44, 144.01, 140.79, 136.73, 135.09, 131.78, 130.35, 130.17, 124.74, 
124.57, 122.93, 118.27, 24.24; MS (Q-TOF ESI) C17H13N2O4 [M-H]- m/z expected = 
309.0881, observed = 309.0895; HPLC-1 = 95%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
(E)-N-(4-(3-(3-nitrophenyl)acryloyl)phenyl)furan-2-carboxamide (19).   
 
Furoic acid (840 mg, 7.49 mmol) was stirred with SOCl2 (5 mL) at 60°C for 1 h, then was 
concentrated.  The intermediate furoyl chloride was stirred with 22 (960 mg, 3.58 mmol) 
and pyridine (0.58 mL, 7.11 mmol) in anhydrous THF (20 mL), and the reaction was left 
to react at room temperature (under Ar).  After 4 h, the reaction was diluted with hexanes 
and the precipitate filtered, rinsed with saturated NaHCO3, 1 M HCl, and water.  The 
precipitate was triturated with EtOAc, filtered, rinsed with EtOAC:hexanes, collected, and 
dried to afford 18 as a tan powder (986 mg, 76% yield).  1H-NMR (300 MHz, d6-DMSO) δ 
10.56 (s, 1H), 8.79 (t, J = 1.7 Hz, 1H), 8.31-8.38 (m, 1H), 8.14-8.30 (m, 4H), 7.96-8.03 
(m, 3H), 7.84 (d, J = 15.7 Hz, 1H), 7.75 (t, J = 8.0 Hz, 1H), 7.43 (dd, J = 3.5, 0.7 Hz, 1H), 
6.74 (dd, J = 3.5, 1.8 Hz, 1H); 13C-NMR (75 MHz, d6-DMSO) δ 187.45, 156.46, 148.45, 
147.12, 146.26, 143.45, 140.92, 136.72, 135.13, 132.34, 130.36, 130.00, 124.74, 
124.60, 122.96, 119.54, 115.61, 112.37; MS (Q-TOF ESI) C20H13N2O5 [M-H]- m/z 
expected = 361.0830, observed = 361.0791; HPLC-1 = 99%; HPLC-2 = 99%. 
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 .......................................................................................................................................... 
(E)-N-(4-(3-(3-nitrophenyl)acryloyl)phenyl)thiophene-2-carboxamide (20).   
 
Pyridine (26.0 μL, 0.319 mmol) was added to a stirring mixture of 22 (71.3 mg, 0.266 
mmol) and thiophene-2-carbonyl chloride (31.5 μL, 0.294 mmol) in anhydrous 
dichloromethane (5 mL) and THF (5 mL), and the reaction was left to stir at room 
temperature (under Ar).  After 18 h, flash chromatographic purification (hexanes:EtOAc 
gradient) afforded 20 as a yellow solid (20.7 mg, 21% yield).  1H-NMR (300 MHz, d6-
DMSO) δ 10.58 (s, 1H), 8.80 (s, 1H), 8.35 (d, J = 7.7 Hz, 1H), 8.16-8.31 (m, 4H), 8.10 
(dd, J = 3.8, 1.0 Hz, 1H), 7.97 (d, J = 8.8 Hz, 2H), 7.92 (dd, J = 5.0, 1.0 Hz, 1H), 7.85 (d, 
J = 15.6 Hz, 1H), 7.72-7.79 (m, 1H), 7.26 (dd, J = 4.9, 3.8 Hz, 1H); MS (Q-TOF ESI) 
C20H13N2O4S [M-H]- m/z expected = 377.0602, observed = 377.0606; HPLC-1 = 98%; 
HPLC-2 = 98%. 
 .......................................................................................................................................... 
(E)-N-(4-(3-(3-nitrophenyl)acryloyl)phenyl)benzamide (21).   
 
Pyridine (45.0 μL, 0.552 mmol) was added to a stirring mixture of 22 (114 mg, 0.423 
mmol) and benzoyl chloride (58.0 μL, 0.503 mmol) in anhydrous THF (5 mL), and the 
reaction was left to stir at room temperature (under Ar).  After 18 h, flash 
chromatographic purification (hexanes:EtOAc gradient) afforded 21 as an orange solid 
(73.3 mg, 46% yield).  1H-NMR (300 MHz, d6-DMSO) δ 10.62 (s, 1H), 8.79 (s, 1H), 8.34 
(d, J = 7.7 Hz, 1H), 8.16-8.30 (m, 4H), 8.03 (2, J = 8.9 Hz, 2H), 7.99 (d, J = 7.5 Hz, 2H), 
7.85 (d, J = 15.7 Hz, 1H), 7.75 (t, J = 8.0 Hz, 1H), 7.51-7.67 (m, 3H); 13C-NMR (75 MHz, 
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d6-DMSO) δ 187.44, 166.08, 148.46, 144.01, 140.91, 136.73, 135.14, 134.57, 132.31, 
131.98, 130.36, 130.01, 128.50, 127.85, 124.75, 124.60, 122.96, 119.54; MS (Q-TOF 
ESI) C22H15N2O4 [M-H]- m/z expected = 371.1037, observed = 371.1055; HPLC-1 = 99%; 
HPLC-2 = 94%. 
General materials and methods for biochemical and cell-based experiments.   
DH5α and BL21 (DE3) E. coli cells were purchased from New England Biolabs, 
and Rosetta™ 2 (DE3) E. coli cells from EMD Millipore.  The human cell viability assays 
were performed using FHC (CRL- 1831), FHS-74Int (CCL-241), DLD-1(CCL-221), HT-
29 (HTB-38) obtained from the ATCC. HCT 116 p53+/+ and p53 -/- were received from Dr. 
Nakshatri. Antibiotics were used in following concentrations when appropriate; 
Kanamycin (34 μg/mL), Ampicillin (50 μg/mL), Chloramphenicol (30 μg/mL) and 
Streptomycin (100 μg/mL).   
NOTE:  While the following experimental protocols have been reported in previous 
studies, by the Johnson lab and others, I have reported detailed descriptions of each 
here in an effort to maintain rigor, reproducibility, and transparency throughout our 
studies. 
E. coli GroEL and GroES purification.   
E. coli GroEL was expressed from a trc-promoted and Amp(+) resistance 
marker plasmid in DH5α. E. coli cells.  GroES was expressed from a T7-promoted and 
Amp(+) resistance plasmid in E. coli BL21 (DE3) cells.  Transformed colonies were 
plated onto Ampicillin-treated LB agar and incubated overnight at 37°C.  Cells were then 
grown at 37°C in Ampicillin-treated LB medium until an OD600 of 0.5 was reached, then 
were induced with 0.8 mM IPTG and continued to grow for 2-3 h at 37°C.  The cultures 
were centrifuged at 14,000 rpm and the cell pellets were collected and re-suspended in 
Buffer A (50 mM Tris-HCl, pH 7.4, and 20 mM NaCl) supplemented with EDTA-free 
complete protease inhibitor cocktail (Roche).  The combined suspension was lysed by 
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sonication, the lysate was centrifuged at 14,000 rpm, and the clarified lysate was passed 
through a 0.45 μm filter (Millipore). 
Anion exchange purification.  
The filtered lysate was loaded onto a GE HiScale Anion exchange column (Q 
Sepharose fast flow anion exchange resin) that was equilibrated with 2 column volumes 
of Buffer A.  The loaded column was washed with 4 column volumes of Buffer A 
containing 30% of Buffer B (50 mM Tris-HCl, pH 7.4, and 1 M NaCl), then bound protein 
was eluted with a 30-60% gradient elution of Buffer B.  Protein-containing fractions, as 
identified by SDS-PAGE, were collected, spin concentrated using a 10 kDa Amicon 
Ultra-15 centrifugal filter (EMD Millipore), and dialyzed overnight with 10 kDa 
SnakeSkin™ dialysis tubing (Thermo Scientific) at 4°C in 50 mM Tris-HCl, pH 7.4, and 
150 mM NaCl solution.  
Size exclusion chromatography.   
The dialyzed protein was loaded onto a Superdex 200 column (HiLoad 26/600, 
GE) that was equilibrated with 2 column volumes of 50 mM Tris-HCl, pH 7.4, and 150 
mM NaCl solution.  The loaded column was eluted with 3 column volumes of 50 mM 
Tris-HCl, pH 7.4, and 150 mM NaCl solution.  Protein-containing fractions, as identified 
by SDS-PAGE, were collected, spin concentrated using a 10 kDa Amicon Ultra-15 
centrifugal filter (EMD Millipore), and dialyzed overnight with 10 kDa SnakeSkin™ 
dialysis tubing (Thermo Scientific) at 4°C in 50 mM Tris-HCl, pH 7.4, and 150 mM NaCl 
solution.  The final protein concentration was determined by Coomassie Protein Assay 
Kit (Thermo Scientific). Batches of GroEL and GroES proteins for testing were stored at 
4°C for up to one month then discarded. 
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Human HSP60 purification.  
 Human HSP60 (mtHSP60) was expressed from a T7-promoted plasmid in 
Rosetta™ 2 (DE3) E. coli using a previously reported plasmid.63  For human HSP60 
purification, a pET21-HSP60 plasmid with an N-terminal octa-Histidine tag was 
transformed into Rosetta™ 2 (DE3) E. coli cells for over-expression.  Cells were grown 
at 37°C in LB / ampicillin / chloramphenicol medium until an OD600 of 0.5 was reached, 
then cultures were induced with 0.5 mM IPTG and continued to grow for 2-3 h at 25°C.  
Cells were centrifuged at 14,000 rpm, and the cell pellet was suspended in 50 mL of 
lysis buffer composed of 100 mM Tris-HCl, pH 7.7, 10 mM MgSO4, 1 mM β-ME, 5% 
glycerol, 0.1% triton X-100, 1500 Units DNAase, 50 mg/ml lysozyme, and one tablet of  
EDTA-free complete protease inhibitor cocktail (Roche). Cells were homogenized and 
passed through a microfluidizer, washing with buffer containing 10 mM Tris-HCl, pH 7.7, 
5% glycerol, and 0.1% triton X-100.  
1st Nickel column purification and His-tag cleavage.  
The cell lysate was centrifuged at 14,000 rpm, then the clarified lysate was 
supplemented with 10 mM imidazole, passed through a 0.2 μm filter, and loaded onto a 
nickel-agarose resin column that was equilibrated with 2 column volume of 20 mM Tris-
HCl pH, 7.7, 5% glycerol, 200 mM NaCl, and 10 mM imidazole.  The sample loaded 
column was washed with 6 column volumes of 50 mM imidazole, then bound HSP60 
was eluted with 500 mM imidazole.  Fractions that were enriched with the His-tagged 
mtHSP60 were collected, concentrated, dialyzed at room temperature for 2 h in 4 L of 20 
mM Tris-HCl, pH 7.7, 200 mM NaCl and 5% glycerol.  Proteolytic cleavage of the His-tag 
was next performed by addition of His-tagged TEV protease at a 1:10 (w:w) ratio, while 
dialyzing over night at 4°C against 4 L of 20 mM Tris-HCl, pH 7.7, 200 mM NaCl, and 
5% glycerol buffer. 
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2nd Nickel column purification.   
The protein sample was loaded onto a second nickel-agarose resin column that 
was equilibrated with 20 mM Tris-HCl, pH 7.7, 5% glycerol, 10 mM NaCl, and 10 mM 
imidazole.  With this column, undigested His-tagged mtHSP60 can be separated from 
digested His-tag removed mtHSP60.  The unbound fractions enriched with His-tag 
cleaved mtHSP60 were collected, and anion exchange chromatography was performed 
on the same day. 
Anion exchange purification of His-tag removed mtHSP60.  
The protein sample was next loaded onto an anion-exchange column that was 
equilibrated with 20 mM Tris-HCl, pH 7.7, and 5% glycerol.  Bound proteins were eluted 
from the column with a linear gradient of 100-400 mM NaCl.  Fractions enriched with 
mtHSP60 were collected, concentrated, and dialyzed in storage buffer (20 mM Tris-HCl, 
pH 7.7, 300 mM NaCl, 5% glycerol, and 10 mM MgCl2) using 10 kDa SnakeSkin™ 
dialysis tubing (Thermo Scientific).  The concentration of protein was determined by 
Coomassie Protein Assay Kit (Thermo Scientific).  Batches of HSP60 protein for testing 
were stored at 4°C for up to two weeks, then discarded.  
Human HSP10 purification.  
Human HSP10 (mtHSP10) was expressed from a T7-promoted (pET3a-HSP10) 
plasmid in Rosetta™ 2 (DE3) pLysS cells.  Cells were grown at 37°C in LB / ampicilin / 
chloramphenicol medium until an OD600 of 0.5 was reached, then were induced with 0.8 
mM IPTG and continued to grow for 2-3 h at 37°C.  The culture was centrifuged at 
14,000 rpm, and the cell pellet was re-suspended in Buffer A (50 mM sodium acetate, 
pH 4.5, and 20 mM NaCl), supplemented with EDTA-free complete protease inhibitor 
cocktail (Roche) and lysed by sonication.  Clarified cell lysate was loaded on a cation 
exchange column (SP Sepharose fast flow resin, GE) and eluted with a linear NaCl 
gradient using Buffer B (50 mM sodium acetate, pH 4.5, and 1 M NaCl).  Fractions 
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containing HSP10 were concentrated, dialyzed with storage buffer (50 mM Tris-HCl, pH 
7.4, and 150 mM NaCl) using 10 kDa SnakeSkin™ dialysis tubing (Thermo Scientific) 
and re-purified on a Superdex 200 column (HiLoad 26/600, GE) in storage buffer.  The 
concentration of protein was determined by Coomassie Protein Assay Kit (Thermo 
Scientific).  Protein was stored at 4°C in 50 mM Tris-HCl, pH 7.4, and 150 mM NaCl.  
Batches of HSP10 protein for testing were stored at 4°C for up to three weeks, then 
discarded.  
Evaluating compounds for inhibition in the GroEL/ES and HSP60/10-mediated 
dMDH refolding assays. 
Reagent preparation.  
For these assays, four primary reagent stocks were prepared: 1) GroEL/ES-
dMDH or HSP60/10-dMDH binary complex stock; 2) ATP initiation stock; 3) EDTA 
quench stock; 4) MDH enzymatic assay stock.  Denatured MDH (dMDH) was prepared 
by 2-fold dilution of MDH (5 mg/ml, soluble pig heart MDH from Roche, product 
#10127248001) with denaturant buffer (7 M guanidine-HCl, 200 mM Tris, pH 7.4, and 50 
mM DTT).  MDH was completely denatured by incubating at room temperature for 45 
min.  The binary complex solutions were prepared by slowly adding the dMDH stock to a 
stirring stock with GroEL (or HSP60) in folding buffer (50 mM Tris-HCl, pH 7.4, 50 mM 
KCl, 10 mM MgCl2, and 1 mM DTT), followed by addition of GroES (or HSP10).  The 
binary complex stocks were prepared immediately prior to dispensing into the assay 
plates and had final protein concentrations of 83.3 nM GroEL or HSP60, 100 nM GroES 
or HSP10, and 20 nM dMDH in folding buffer.  For the ATP initiation stock, ATP solid 
was diluted into folding buffer to a final concentration of 2.5 mM.  Quench solution 
contained 600 mM EDTA (pH 8.0).  The MDH enzymatic assay stock consisted of 20 
mM sodium mesoxalate and 2.4 mM NADH in reaction buffer (50 mM Tris-HCl, pH 7.4, 
50 mM KCl, and 1 mM DTT). 
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Assay protocol.  
First, 30 µL aliquots of the GroEL/ES-dMDH or HSP60/10-dMDH binary complex 
stocks were dispensed into clear, 384-well polystyrene plates.  Next, 0.5 µL of the 
compound stocks (10 mM to 4.6 µM, 3-fold dilutions series in DMSO) were added by 
pin-transfer (V&P Scientific).  The chaperonin-mediated refolding cycles were initiated by 
addition of 20 µL of ATP stock (reagent concentrations during refolding cycle: 50 nM 
GroEL or HSP60, 60 nM GroES or HSP10, 12 nM dMDH, 1 mM ATP, and compounds of 
100 µM to 46 nM, 3-fold dilution series). The refolding reactions were incubated at 37°C. 
The incubation time was determined from refolding time-course control experiments until 
they reached ~90% completion of refolding cycle – generally ~20-40 min for GroEL/ES, 
and ~40-60 min for HSP60/10).  Next, the assay was quenched by addition of 10 µL of 
the EDTA to final concentration of 100 mM.  Enzymatic activity of the refolded MDH was 
initiated by addition of 20 µL MDH enzymatic assay stock (20 mM sodium mesoxalate 
and 2.4 mM NADH in reaction buffer, 50 mM Tris pH 7.4, 50 mM KCl, 1 mM DTT), and 
followed by measuring the NADH absorbance in each well at 340 nm using a Molecular 
Devices SpectraMax Plus384 microplate reader (NADH absorbs at 340 nm, while NAD+ 
does not).  A340 nm measurements were recorded at 0.5 minutes (start point) and at 
successive time points until the amount of NADH consumed reached ~90% (end point, 
generally between 20-35 minutes).  The differences between the start and end point A340 
values were used to calculate the % inhibition of the GroEL/ES or HSP60/10 machinery 
by the compounds.  IC50 values for the test compounds were obtained by plotting the % 
inhibition results in GraphPad Prism and analyzing by non-linear regression using the 
log (inhibitor) vs. response (variable slope) equation.  Results presented represent the 
averages of IC50 values obtained from at least seven replicates. 
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Counter screening compounds for inhibition of native MDH enzymatic activity. 
Reagent preparations & assay protocol.   
This assay was performed as described above for the GroEL/ES-dMDH refolding 
assay; however, the assay protocol differed in the sequence of compound addition to the 
assay plates. The refolding reactions were allowed to proceed for 45 min at 37°C in the 
absence of test compounds (complete refolding of MDH occurs), then quenched with the 
EDTA stock.  Compounds were then pin transferred into the plates after the EDTA 
quenching step; thus, compound effects are only possible by inhibiting the fully refolded 
MDH reporter substrate.  Next enzymatic activity of the refolded MDH was initiated by 
addition of 20 µL MDH enzymatic assay stock (20 mM sodium mesoxalate and 2.4 mM 
NADH in reaction buffer, 50 mM Tris pH 7.4, 50 mM KCl, 1 mM DTT), and followed by 
measuring the NADH absorbance in each well at 340 nm using a Molecular Devices 
SpectraMax Plus384 microplate reader (NADH absorbs at 340 nm, while NAD+ does 
not).  A340 nm measurements were recorded at 0.5 minutes (start point) and at successive 
time points until the amount of NADH consumed reached ~90% (end point, generally 
between 20-35 minutes). Compounds were tested in 8-point, 3-fold dilution series (62.5 
µM to 29 nM during the reporter reaction) in clear, flat-bottom 384-well microtiter plates.  
DMSO was used as negative control, and previously discovered native MDH inhibitors 
were used as positive controls.  IC50 values for the test compounds were obtained by 
plotting the % inhibition results in GraphPad Prism and analyzing by non-linear 
regression using the log (inhibitor) vs. response (variable slope) equation.  Results 
presented represent the averages of IC50 values obtained from at least nine replicates. 
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Evaluating compounds for inhibition in the GroEL/ES-mediated dRho refolding 
assay. 
Reagent preparation.  
For this assay, five primary reagent stocks were prepared: 1) GroEL/ES-dRho 
binary complex stock; 2) ATP initiation stock; 3) thiocyanate enzymatic assay stock; 4) 
formaldehyde quench stock; 5) ferric nitrate reporter stock.  Denatured rhodanese 
(dRho) was prepared by 3-fold dilution of rhodanese (Roche product #R1756, diluted to 
10 mg/mL with H2O) with denaturant buffer (12 M Urea, 50 mM Tris-HCl, pH 7.4, and 10 
mM DTT).  Rhodanese was completely denatured by incubating at room temperature for 
45 min.  The binary complex solution was prepared by slowly adding the dRho stock to a 
stirring stock of concentrated GroEL in modified folding buffer (50 mM Tris-HCl, pH 7.4, 
50 mM KCl, 10 mM MgCl2, 5 mM Na2S2O3, and 1 mM DTT).  The solution was 
centrifuged at 16,000 x g for 5 minutes, and the supernatant was collected and added to 
a solution of GroES in modified folding buffer to give final protein concentrations of 100 
nM GroEL, 120 nM GroES, and 80 nM dRho.  The binary complex stock was prepared 
immediately prior to use.  For the ATP initiation stock, ATP solid was diluted into 
modified folding buffer to a final concentration of 2.0 mM.  The thiocyanate enzymatic 
assay stock was prepared to contain 70 mM KH2PO4, 80 mM KCN, and 80 mM Na2S2O3 
in water.  The formaldehyde quench solution contained 30% formaldehyde in water.  The 
ferric nitrate reporter stock contained 8.5% w/v Fe(NO3)3 and 11.3% v/v HNO3 in water. 
Assay protocol.   
First, 10 mL aliquots of the GroEL/ES-dRho complex stock were dispensed into 
clear, 384-well polystyrene plates.  Next, 0.5 µL of the compound stocks (10 mM to 4.6 
µM, 3-fold dilutions in DMSO) were added by pin-transfer.  The chaperonin-mediated 
refolding cycle was initiated by addition of 10 µL of ATP stock (reagent concentrations 
during refolding cycle: 50 nM GroEL, 60 nM GroES, 40 nM dRho, 1 mM ATP, and 
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compounds of 250 µM to 114 nM, 3-fold dilution series).  After incubating for 45 minutes 
at 37°C for the refolding cycle, 30 µL of the thiocyanate enzymatic assay stock was 
added and incubated for 60 min at R.T. for the refolded rhodenase enzymatic reporter 
reaction.  The reporter reaction was quenched by adding 10 µL of the formaldehyde 
quench stock, and then 40 µL of the ferric nitrate reporter stock was added to quantify 
the amount of thiocyanate produced during the enzymatic reporter reaction, which is 
proportional to the amount of dRho refolded by GroEL/ES.  After incubating at R.T. for 
15 min, the absorbance by Fe(SCN)3 was measured at 460 nm using a Molecular 
Devices SpectraMax Plus384 microplate reader.  A second set of baseline control plates 
were prepared analogously, but without GroEL/ES-dRho protein binary solution, to 
correct for possible interference from compound absorbance or turbidity.  IC50 values for 
the test compounds were obtained by plotting the A460 results in GraphPad Prism and 
analyzing by non-linear regression using the log(inhibitor) vs. response (variable slope) 
equation.  Results presented represent the averages of IC50 values obtained from at 
least seven replicates. 
Counter screening compounds for inhibition of native rhodanese enzymatic 
activity. 
Reagent preparations & assay protocol.  
Reagents were identical to those used in the GroEL/ES-dRho refolding assay 
described above; however, the assay protocol differed in the sequence of compound 
addition to the wells.  Compounds were pin transferred after the 60 minute incubation for 
the refolding cycle, but prior to the addition of the thiocyanate enzymatic assay stock.  
Thus, the refolding reactions were allowed to proceed for 60 min at 37°C in the absence 
of test compounds, but the enzymatic activity of the refolded rhodanese reporter enzyme 
was monitored in the presence of test compounds (inhibitor concentration range during 
the enzymatic reporter reaction is 100 µM to 46 nM – 3-fold dilutions).  IC50 values for 
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the rhodanese reporter enzyme were determined as described above.  Results 
presented represent the averages of IC50 values obtained from at least seven replicates. 
Evaluating chalcones for effects on the viability of non-cancerous colon (FHC) 
and intestine (FHs-74 Int) cells, colorectal cancer cells (HCT 116 p53+/+ and p53-/-, 
DLD-1, HT-29).  
Evaluation of compound cytotoxicity’s to all the non-cancerous and colorectal 
cancer cells was performed using Alamar Blue-based viability assays. The FHC cell 
lines were maintained in DMEM: F12 medium (CC-1831) supplemented with the 10 mM 
HEPES, 10 ng/ml cholera toxin, 0.005 mg/ml insulin, 0.005 mg/ml transferrin, 100 ng/ml 
hydrocortisone, 20 ng/ml human recombinant EGF (as listed on ATCC), 100 units/ml 
penicillin, 100 µg/ml streptomycin and 10% FBS. FHs 74-Int cells were maintained in 
Hybri-Care Medium medium 46-X supplemented with 100 units/ml penicillin, 100 µg/ml 
streptomycin and 10% FBS. HCT 116 p53+/+ and HCT 116 p53-/-, HT-29 and DLD-1 cell 
lines were maintained in RPMI-1640 Medium and to make a complete medium it was 
supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin and 10% FBS. 
All assays were carried out in 384-well plates (BRAND cell culture grade plates, 
781980).  Cells at 80% confluence were harvested and diluted in growth medium, then 
45 µL of the respective cells (1,500 cells/well) were dispensed per well, and plates were 
sealed with "Breathe Easy" oxygen permeable membranes (Diversified Biotech) and 
incubated at 37°C, 5% CO2, for 24 h. The following day, 1 µL of the compound stocks 
(10 mM to 4.6 µM, 3-fold dilutions in DMSO) were pre-diluted by pin-transfer into 25 µL 
of the relevant growth mediums. Then, 15 µL aliquots of the diluted compounds were 
added to the cell assay plates to give inhibitor concentration ranges of 100 μM to 46 nM 
during the assay (final DMSO concentration of 1% was maintained during the assay). 
Plates were sealed with "Breathe Easy" oxygen permeable membranes and incubated 
for an additional 48 h at 37°C and 5% CO2. The Alamar Blue reporter reagents were 
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then added to a final concentration of 10%, the plates incubated at 37°C and 5% CO2, 
and sample fluorescence (535 nm excitation, 590 nm emission) was read using a 
Molecular Devices Flex Station II 384-well plate reader (readings taken between 4-24 h 
of incubation so as to achieve signals in the 30-60% range for conversion of resazurin to 
resorufin). Cell viability was calculated as per vendor instructions (Thermo Fisher - 
Alamar Blue cell viability assay manual). Cytotoxicity CC50 values for the test 
compounds were obtained by plotting the % resazurin reduction results in GraphPad 
Prism and analyzing by non-linear regression using the log(inhibitor) vs. response 
(variable slope) equation. Results presented represent the averages of CC50 values 
obtained from at least six replicates for all the cell lines. 
Evaluating chalcone lead analogs for their ability to inhibit colony formation of HCT 
116 p53+/+ cells.   
500 HCT 116 p53+/+ cells per well were dispensed into 6 well culture plates and 
incubated for 72 hours with compounds 19-21, with compound concentrations ranging 
from 100 µM to 0.045 µM (3-fold dilution series). Incubation conditions were as 
described above for the Alamar Blue cell viability assay. After the 72 hours, the media 
was replaced with the fresh media and the cells were incubated for a further 7 days in 
the absence of test compounds. Cells were then fixed and stained with a 0.1% w/v 
crystal violet/ethanol solution, and colonies counted manually by visual inspection. The 
plating efficiency factor was calculated by the ratio of the number of cells surviving 
(colonies identified) to the number of cells seeded (500). Then, the surviving fraction of 
cells in the presence of test compounds was normalized to that obtained in the absence 
of any compound. In addition, for each well, total area covered by colonies was obtained 
with a house made ImageJ macro based on the Analyze particle function. Then, the 
average area per colony values were determined as the ratio of total surface area 
covered by the colonies divided by number of individual colonies. Results presented 
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represent the averages values obtained from at least six replicates. Test compound EC50 
values were obtained by plotting the % surviving fraction and average colony size results 
in GraphPad Prism and analyzing by non-linear regression using the log(inhibitor) vs. 
response (variable slope) equation. 
Evaluating lead chalcone analogs for their ability to inhibit in a wound healing assay 
using HCT 116 p53+/+ cells. 
75,000 HCT 116 p53+/+ cells per well were dispensed in 96-well Image Lock 
plates (Essen Bioscience) and incubated as in the Alamar Blue cell viability assay until 
an 80% confluent monolayer was formed. Linear wounds were then introduced using a 
Wound Maker 96 tool (Essen Bioscience), and the wells was replaced fresh media and 
incubated for 48 hours with compounds 19-21 in an IncuCyte S3 Live Cell Analysis 
System, with compound concentrations ranging from 100 µM to 0.045 µM (3-fold dilution 
series). Incubation conditions were as described above for the Alamar Blue cell viability 
and clonogenicity assays. Plates were imaged every hour to determine the time-course 
of wound closure in each well; however, wound closure analyses were conducted using 
the 0 and 26 hour time points, where wounds for the 1% DMSO vehicle treated wells 
reached 90% closure. As compound precipitation at the 33 and 100 µM concentrations 
prevented the Incucyte software from being able to process the images in an automated 
manner, we manually counted wound distances for all the compounds and 
concentrations using ImageJ software: five distances were measured manually for each 
well at both 0 and 26 hours, and percent wound closures were determined as an 
average of these five distance measurements and taking the ratio between the wound 
width at t = 26 hours to the initial wound width.  Results presented represent the 
averages values obtained from at least eight replicates. Test compound EC50 values 
were obtained by plotting the % wound closure results in GraphPad Prism and analyzing 
by non-linear regression using the log(inhibitor) vs. response (variable slope) equation. 
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Control compounds, calculation of I/E/CC50 values, and statistical considerations. 
For all the assays, DMSO was used as negative control. For the GroEL/ES and 
HSP60/10-mediated dMDH and dRho refolding assays, and native MDH and Rho 
enzymatic activity counter-screens, a panel of our previously discovered and reported 
chaperonin inhibitors were used as positive controls e.g. compounds 8,9 and 18 from 
Johnson et. al 2014 and Abdeen et. al 2016,41, 60 suramin and compound 2h-p from 
Abdeen et. al 2016; 64 compounds 20R, 20L and 28R from Abdeen et. al 2018; 65 and 
closantel and rafoxanide from Kunkle et. al 2018.66 For the human cell viability assays, 
control compounds include the aforementioned compounds as well as other protein 
homeostasis inhibitor, such as bortezomib (proteasome inhibitor); VER-155008 (HSP70 
inhibitor); and ganetespib and 17- DMAG (HSP90 inhibitors). 
All IC50/EC50/CC50 results reported are averages of values determined from 
individual dose-response curves in assay replicates as follows: 1) Individual I/E/CC50 
values from assay replicates were first log-transformed and the average log(I/E/CC50) 
values and standard deviations (SD) calculated; 2) Replicate log(I/E/CC50) values were 
evaluated for outliers using ROUT method in GraphPad Prism (Q of 10%); and 3) 
Average I/E/CC50 values were then back calculated from the average log(I/E/CC50) 
values. To compare log(I/E/CC50) values between different assays, two-tailed Pearson 
correlation analysis were performed using GraphPad Prism (95% confidence level). For 
compounds were log(I/E/CC50) values were greater than the maximum compound 
concentrations tested (i.e. >1.8, >2.0, and >2.4 - or >63, >100, and >250 µM, 
respectively), results were represented as 0.1 log units higher than the maximum 
concentrations tested (i.e. 1.9, 2.1, and 2.5 – or 79,126 and 316 µM, respectively) so as 
not to overly bias comparisons because of the unavailability of definitive values for these 
inactive compounds.  
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APPENDIX – SUPPLEMENTAL TABLES 
Table S4- Log-transformed values ± SD of Table 4 biochemical assay results. 
 
Rho MDH Rho MDH
1 >2 >1.8 >2.4 >2 >2
2 >2 >1.8 >2.4 >2 >2
3 >2 >1.8 >2.4 >2 >2
4 >2 >1.8 1.43 ± 0.09 0.85 ± 0.19 0.94 ± 0.20
5 1.60 ± 0.55 >1.8 0.09 ± 0.17 0.29 ± 0.33 0.79 ± 0.22
6 >2 >1.8 1.79 ± 0.16 1.31 ± 0.22 1.31 ± 0.15
7 >2 >1.8 1.53 ± 0.22 1.12 ± 0.28 1.21 ± 0.20
8 >2 >1.8 1.59 ± 0.18 1.31 ± 0.21 1.33 ± 0.19
9 >2 >1.8 1.66 ± 0.23 1.42 ± 0.31 1.34 ± 0.16
10 1.74 ± 0.24 1.66 ± 0.21 1.07 ± 0.18 0.77 ± 0.33 0.99 ± 0.21
11 >2 >1.8 1.83 ± 0.08 1.61 ± 0.21 1.64 ± 0.15
12 >2 >1.8 0.61 ± 0.47 0.62 ± 0.27 1.02 ± 0.23
13 >2 >1.8 1.57 ± 0.14 1.33 ± 0.25 1.30 ± 0.14
14 >2 >1.8 2.13 ± 0.14 1.76 ± 0.21 1.63 ± 0.17
15 >2 >1.8 1.60 ± 0.11 0.98 ± 0.14 1.15 ± 0.18
16 >2 >1.8 1.30 ± 0.23 0.58 ± 0.25 0.67 ± 0.27
17 >2 >1.8 1.43 ± 0.13 0.63 ± 0.32 0.77 ± 0.31
18 >2 >1.8 0.96 ± 0.08 0.32 ± 0.24 0.89 ± 0.25
19 >2 >1.8 0.39 ± 0.33 -0.14 ± 0.23 0.39 ± 0.30
20 >2 >1.8 0.40 ± 0.10 -0.41 ± 0.32 0.37 ± 0.21
21 >2 >1.8 0.74 ± 0.09 -0.10 ± 0.29 0.36 ± 0.20
HSP60/10-dMDH 
Refolding
Native Reporter Counter-Screens GroEL/ES-mediated Refolding of:
Biochemical Assay log(IC50)
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Table S5- Log-transformed values ± SD of Table 5 cell viability assay results. 
 
 
 
p53
+/+ 
p53
-/- 
1 >2 >2 >2 >2 >2 >2
2 >2 >2 >2 >2 >2 >2
3 >2 >2 >2 >2 >2 >2
4 1.56 ± 0.09 1.85 ± 0.13 0.98 ± 0.20 1.05 ± 0.23 1.40 ± 0.05 1.16 ± 0.18
5 1.09 ± 0.23 1.45 ± 0.35 0.76 ± 0.26 0.79 ± 0.29 0.98 ± 0.15 0.92 ± 0.12
6 1.84 ± 0.37 1.91 ± 0.07 1.30 ± 0.16 1.33 ± 0.17 1.53 ± 0.10 1.47 ± 0.08
7 1.53 ± 0.01 1.92 ± 0.02 1.19 ± 0.22 1.23 ± 0.20 1.55 ± 0.10 1.37 ± 0.21
8 >2 2.0 ± 0.01 1.50 ± 0.21 1.51 ± 0.16 1.70 ± 0.09 1.59 ± 0.18
9 1.90 ± 0.08 1.99 ± 0.06 1.34 ± 0.22 1.48 ± 0.16 1.71 ± 0.16 1.50 ± 0.20
10 1.79 ± 0.01 1.95 ± 0.05 1.32 ± 0.17 1.37 ± 0.29 1.49 ± 0.09 1.45 ± 0.29
11 1.93 ± 0.12 >2 1.75 ± 0.24 1.86 ± 0.15 1.92 ± 0.06 1.95 ± 0.05
12 1.89 ± 0.06 1.94 ± 0.13 1.60 ± 0.32 1.72 ± 0.19 1.78 ± 0.16 1.73 ± 0.28
13 1.99 ± 0.13 >2 1.62 ± 0.26 1.77 ± 0.22 1.84 ± 0.04 1.88 ± 0.11
14 1.95 ± 0.07 >2 1.43 ± 0.12 1.37 ± 0.14 1.52 ± 0.04 1.54 ± 0.09
15 1.57 ± 0.44 1.93 ± 0.03 1.03 ± 0.21 1.06 ± 0.17 1.44 ± 0.06 1.12 ± 0.27
16 1.39 ± 0.39 1.92 ± 0.12 1.10 ± 0.26 1.21 ± 0.20 1.55 ± 0.13 1.45 ± 0.10
17 1.83 ± 0.27 1.86 ± 0.18 1.24 ± 0.21 1.45 ± 0.18 1.67 ± 0.14 1.55 ± 0.22
18 1.02 ± 0.10 1.26 ± 0.40 0.23 ± 0.27 0.26 ± 0.26 0.80 ± 0.15 0.31 ± 0.32
19 >2 >2 0.51 ± 0.39 0.61 ± 0.27 1.49 ± 0.22 0.44 ± 0.17
20 1.59 ± 0.44 1.84 ± 0.24 0.42 ± 0.23 0.39 ± 0.17 1.05 ± 0.24 0.41 ± 0.14
21 >2 >2 0.62 ± 0.12 1.40 ± 0.69 >2 0.59 ± 0.18
Colon Cancer CellsNon-Cancer Cells
FHS-74Int 
(Instestine)
FHC 
(Colon)
DLD-1
HCT 116
Cell Viability log(EC50)
HT-29
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